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ABSTRACT 
 
 
Background: The etiology and pathology of nasal polyposis are 
mainly unknown. It seems to be partially related to infection but it is 
mainly related to eosinophilic inflammatory mechanism as in 
acetylsalicylic acid (ASA) intolerance or asthma. The purpose of the 
present study was 1) to deepen the understanding of the clinical course 
of nasal polyposis over a long period of time, 2) to examine the 
reliability of A-mode ultrasound (A-US) in detecting fluid retention or 
mucosal thickening in patients with chronic polypoid sinusitis, 3) to 
analyse the sense of smell in patients with long-standing nasal 
polyposis as compared to a healthy control material, 4) to investigate 
the occurrence of VPF/VEGF in nasal polyps of patients with chronic 
nasal polyposis for two decades as compared to normal nasal mucosa 
and 5) to find out the frequency of the two most common CF 
mutations in patients with chronic sinusitis with or without nasal 
polyps. 
Materials and methods: Studies I-IV were based on a series of 109 
patients who underwent polypectomy at the Department of 
Otorhinolaryngology, University Central Hospital, Helsinki in 1977-
78. The patients were then divided into three groups (ASA intolerance, 
atopic (AT) and intrinsic allergy-like disease (INTR)) according to the 
results of clinical and allergological investigations. Forty-one of those 
109 patients were after about twenty years re-evaluated and classified 
as earlier into three groups and examined as follows: physical 
examination, sinus computed tomography (CT), A-US, olfactory 
threshold measurement, odour detection test, skin prick tests, nasal 
smears, active anterior rhinomanometry, acoustic rhinometry and a 
biopsy from a polyp or from the mucosa of the middle turbinate, if no 
polyp was seen. Information on nasal symptoms, present and past 
history of nasal disorders was gathered by means of a questionnaire 
completed by all subjects. A-US examination (done twice by two 
investigators) of the maxillary sinus and sinus CT were done in the 
course of 2 hours. The two investigators had no knowledge of patient 
history, CT findings or the other investigator’s results. The ultrasound 
findings recorded by investigator 1 were carefully analysed for 
reliability by comparison with CT evidence. The results obtained by 
investigator 2 were used to assess the reproducibility of A-US 
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diagnoses. Vascular permeability/vascular endothelial growth factor 
(VPF/VEGF) expression was determined using a mouse monoclonal 
antihuman VPF/VEGF antibody. In study V the determination of 
cystic fibrosis gene mutation carriers (394delTT and F508) were 
done in 127 patients with chronic sinusitis. Genomic DNA was 
isolated from the whole blood specimens according to standard 
protocols. Positive controls from CF patients were used. 
Results: Sixty-eight percent of 41 patients thought that during 20 
years the activity of their disease had decreased or the disease had 
resolved. However polyps could be seen in anterior rhinoscopy in 85% 
of the patients. The patients with ASA intolerance had a higher 
recurrence frequency, a greater need for surgical treatment than the 
patients in the AT and INTR groups. The sensitivity of A-US in 
detecting fluid or total obliteration was 30% and the specificity 81%. 
In detecting mucosal thickening the sensitivity of A-US was 40% and 
the specificity 48%. The two investigators obtained identical A-US 
results in only 50%. Forty-six percent of patients had anosmia or 
hyposmia. The association between total obliteration of both olfactory 
recesses and olfactory thresholds was statistically significant. In the 
forward stepwise multiple linear regression analysis of all patients, the 
degree of obliteration of ethmoidal sinuses in CT, polyposis seen in 
anterior rhinoscopy, the logarithmically transformed total nasal 
resistance and gender showed significant association with olfactory 
thresholds. The staining for VPF/VEGF in the mucosal surface and in 
the glandular epithelium of nasal polyps was weaker than in normal 
controls. In two patients strong staining for VPF/VEGF was found in 
granules of mast cells. One carrier of the 394delTT mutation was 
found among 127 chronic sinusitis patients. 
Conclusion: This study shows that the activity of nasal polyposis does 
not cease in the course of 20 years. Although A-US can be a valuable 
investigation method in a simple acute sinusitis, it should not be used 
in patients with chronic sinusitis history, polyposis and especially in 
transantrally operated maxillary sinuses. Chronic nasal polyposis 
diminishes the sense of smell. The expression of VPF/VEGF seems to 
be weaker in polyps than in normal nasal mucosa but strong staining 
of VPF/VEGF in mast cells needs further study to find out its 
meaning. Routine screening of sinusitis patients for CF mutations 
gives no more information on the etiology of chronic sinusitis in 
Finnish population.
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ABBREVIATIONS 
 
 
AFS = allergic fungal sinusitis  
ALU = arbitrary logarithmic unit 
AMP = adenosine monophosphate 
ANOVA = analysis of variance  
ASA = acetylsalicylic acid 
AT = atopic 
A-US = A-mode ultrasound  
bFGF = basic fibroblast growth factor 
B-US = B-mode ultrasound  
CF = cystic fibrosis 
CFGAC = the Cystic Fibrosis Genetic Analysis Consortium 
CFTR = cystic fibrosis transmembrane conductance regulator 
CT = computed tomography 
DNA = deoxyribonucleic acid  
DS = decismel 
ECP = eosinophil cationic protein 
ELISA = enzyme-linked immunosorbent assay 
ENT = Ear, Nose and Throat 
EPO = eosinophil peroxidase 
flt-1 = fms-like-tyrosine kinase-1 
Ig = immunoglobulin  
IGF-I = insulinlike growth factor I  
IL = interleukin  
INTR = intrinsic allergy-like disease 
KDR = kinase domain region 
LT = leukotriene 
MBP = major basic protein 
MRI = magnetic resonance imaging 
mRNA = messenger ribonucleic acid 
NARES = nonallergic rhinitis with eosinophilia syndrome 
PAF = platelet activating factor  
PCD = primary ciliary dyskinesia 
PCR = polymerase chain reaction  
PG = prostaglandin  
RANTES = regulated upon activation, normal T-cell expressed and 
secreted 
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SD = standard deviation 
 
US = ultrasound 
UPSIT = the University of Pennsylvania Smell Identification Test 
VCAM-1 = vascular cell adhesion molecule 1 
VPF/VEGF = vascular permeability/vascular endothelial growth factor  
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1. INTRODUCTION 
 
 
The history of nasal polyposis goes back nearly 5000 years to Ancient 
Egypt, although the exact details are obscure (Brain 1997). The 
prevalence of nasal polyps is reported as 1-2% of the adult population 
in Europe (Hosemann et al. 1994) and 4.3% in Finland (Hedman et al. 
1999). The predominance of males over females is a ratio of 2-4:1 
(Drake Lee 1987).  
 
Several conditions and symptoms are related to the occurrence of nasal 
polyps. In asthmatic patients occurrence rates from 7% to 42% have 
been reported (Weille 1936, Settipane and Chafee 1977, Maran and 
Lund 1990). Nasal polyps are common in patients with acetylsalicylic 
acid (ASA) intolerance, the frequency going up 40% to 60% of these 
patients (Maran and Lund 1990). A comorbid disease with nasal 
polyposis is cystic fibrosis (CF), which is one of the most frequent 
hereditary diseases found in Caucasians. Polyps are found in adult 
patients with CF in 20-48% (di Sant’ Agnese and Davis 1979, Aitken 
and Fiel 1993). Nasal polyps are also strongly associated with chronic 
rhinosinusitis of different origin (Maran and Lund 1990). 
 
Nasal polyps are usually bilateral, multiple, and freely movable 
smooth tumours. Clinical symptoms are obstruction of the airflow 
through the nose, often hyp- or anosmia, postnasal dripping and nasal 
secretion. Systemic or intranasal steroids are commonly used in their 
treatment, but in cases of serious blockage or infectious complications 
also surgery is indicated. The recurrence of nasal polyposis constitutes 
a serious clinical problem. Recurrence rates up to 29-53% have been 
reported (Blumstein and Tuft 1957, Jäntti-Alanko et al. 1985, Larsen 
and Tos 1994). Nasal polyposis can be a frustrating disease for the 
patient and for the treating physician. 
 
The etiology and pathophysiology of nasal polyposis are still mainly 
unknown though significant knowledge has been obtained about nasal 
physiology and nasal polyposis with scientific advances in the fields of 
biochemistry, microbiology, and immunology. In recent years, several 
studies have drawn attention to e.g. growth factors in nasal polyps. 
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Before effective prevention and treatment of the disease can be 
achieved, more knowledge is needed about nasal polyposis. 
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2. REVIEW OF THE LITERATURE 
 
 
2.1. HISTORY OF NASAL POLYPS 
 
The history of nasal polyps goes back over 4000 years to Ancient 
Egypt. Further significant advances were made in Ancient Greece and 
Renaissance Europe. The first known medical practitioner was an 
Egyptian rhinologist called Ni-Ankh Sekhmet who was the Court 
Physician to King Sahura and his picture together with that of his wife 
were found on a slab in the tomb of the king together with a testimony 
of royal gratitude which states ”he has made his nostrils well” (Brain 
1997). It has been shown that the Egyptians were familiar with nasal 
polyps, which they described as ”grapes coming down from the nose”. 
Treatment included medicaments containing alcohol and it is possible 
that some of the Egyptian surgical instruments may well have been 
used to remove polyps (Pahor and Kimura 1991). Hippocrates (460-
370 B.C.), the ”Father of Medicine” thought that polyp disease 
resulted from a disturbed equilibrium between the 4 ”humours”. When 
the humours were too thick it could result in the development of 
polyps (Brain 1997). He developed a technique for removal of polyps, 
which was included in textbooks as late as that of Voltolini’s in 1888 
(Vancil 1969). This method was the ”sponge” method in which the 
ends of three or four strings were tied to a sponge cut to the proper 
size and shape. The other ends were knotted together and fastened to 
the eye of a malleable tin or lead probe, which was then passed 
through the nose and into the pharynx. The secured ends of the strings 
were passed over the end of a forked probe held in the pharynx. The 
polyps were delivered with the sponge with a successful manoeuvre. 
For harder growths, he used the described technique, but he 
substituted a loop of sinew for the sponge and adjusted it around the 
polyp before applying traction. He also used cauterisation with hot 
iron through a hollow tube serving as a speculum. Polypectomy was 
followed by the local application of copperas caustic powder and the 
insertion of small lead plates smeared with oil and honey (Vancil 
1969).  
 
Paulus of Aegina (625-690 A.D.), a physician of high reputation in 
Alexandria, believed that the ethmoid cells were the origin of nasal 
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polyps. He devised a rather barbarous method for polyp removal. 
”Taking, then, a thread moderately thick, like a cord, and having tied 
knots upon it at the distance of two or three finger breadths, we 
introduce it into the opening of a double-headed speculum (probe) and 
we push the other extremity of the speculum upward to the ethmoid 
openings passing it by the palate and mouth; and then, drawing it by 
two hands, we saw away, as it were, with the knots, the fleshy bodies. 
After the operation, we keep the opening separate by means of a tent 
resembling the wick of a lamp.” Postoperatively he sponged the parts 
carefully and injected oxycrate of wine into the nose. If fluids 
descended by the roof of the mouth to the pharynx, the operation had 
succeeded (Vancil 1969).  
 
In the era of Arabian Medicine Avicenna (980-1037 A.D.) described 
nasal polyps as ”piles in the nose” or haemorrhoids” in the nose. 
Abulcasis (1013-1106 A.D.), the greatest of the Arab surgeons used 
cautery and pulled the nasal polyp forward with a hook, cut through 
the pedicle with scissors and then washed the nasal cavity with vinegar 
(Pahor and Kimura 1991). 
 
In the Middle Ages at the 11th and 12th century, the School of Salerno 
flourished and Greek and Arabian medical books were translated into 
Latin. Garlic was inserted into the nose after being wrapped in cloth 
leading to sneezing and ”expulsion” of the polyps. Polyps were 
removed with knives, hot rods and forceps (Pahor and Kimura 1991). 
 
In Renaissance Forestus (1522-1597 A.D.) recorded a case history 
which showed that the theory of 4 ”humours” did linger on to much 
more recent times. (Pahor and Kimura 1991, Brain 1997). In the case 
of anosmia he stated that if it is from ethmoidal obstruction, or from 
the humour discharged from a catarrh, the latter must first be cured 
(Vancil 1969). Forestus described a case of a woman in whose nostrils 
a huge polyp had grown due to her carrying heavy weights on her 
head, which forced the mucus down into the membranes of her nose. 
She was cured by ligation of the polyp and the application of vitriol to 
its stump but it recurred when the woman resumed her occupation and 
it was again cured in the same way (Brain 1997). 
 
Fallopius (1523-1562 A.D.) used ligatures, leaving them around the 
anterior polyps for two or three days, when they would fall off with 
the constricted mass. For posterior polyps, which he considered as 
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haemorrhoids, he designed the first major advancement in the 
principle of the snare, since Hippocrates. The same instruments he 
also used for rectal polyps (Vancil 1969). 
 
The operations were in fact unsatisfactory because they were always 
painful, and potentially dangerous because the surgeon nearly always 
had a lack of visual control. Further impetus was gained when Carl 
Koller, in 1884, discovered the surgical possibilities of cocaine 
(Vancil 1969). Nasal polypectomy did not become a routine minor 
operation until the end of the 19th century (Brain 1997). As early as 
1901 Hirschman used a 4 mm cystoscope to get a better view into the 
nasal cavities and nasopharynx (Hirschman 1903) and in the late 
1960’s and early 1970’s Messerklinger from Graz in Austria 
developed a technique of systematic endoscopic investigation 
(Stammberger 1997). Nowadays nasal snares are improved in design 
and we have endoscopes, shavers, silver nitrate sticks, electro-cautery 
and many types of nasal decongestants and steroids at our disposal. 
 
 
2.2. EPIDEMIOLOGY 
 
2.2.1. The prevalence of nasal polyps 
 
The prevalence of nasal polyps is reported as 1-2% of the adult 
population in Europe (Hosemann et al. 1994) and 4.3% in Finland 
(Hedman et al. 1999). The prevalence of nasal polyposis has been 
estimated to be about 4% in patient referrals to allergy clinics in USA 
but it has been reported to be much higher in selected populations 
(Settipane and Chaffee 1977, Maran and Lund 1990). In a study on 
cadavers, 42% were found to have nasal polyps (Larsen and Tos 
1996). The predominance of males over females is with ratio of 2-4:1 
(Drake Lee 1987). The manifestation of nasal polyps is usually after 
the age of 20 years. Initial presentation occurs then equally in each 
decade up to 60 years, but after this they are encountered more rarely. 
They are also considered to become less troublesome as the patient 
ages (Drake-Lee 1994). Nasal polyps in children are very rare – an 
incidence of 0.1% has been reported (Settipane and Chafee 1977). 
Nasal polyps are rare in animals and the chimpanzee is the only animal 
known to suffer from a similar polyposis as humans (Drake-Lee 
1987). 
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2.2.2. Nasal polyps and CF 
 
Long known to be an autosomal-recessive illness, CF was found in 
1989 to be caused by a mutation of a normal gene on the long arm of 
chromosome 7. The gene is known as the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene (Kerem et al. 
1989, Riordan et al. 1989, Rommens et al. 1989). The CFTR gene 
codes for a protein that functions as a cyclic adenosine 
monophosphate (AMP)-regulated chloride channel. CFTR protein is 
expressed on the lumenal surface of pancreatic and sweat gland 
epithelial cells and in submucosal glands and epithelium lining the 
airways (Deane and Schwartz 1997). To date, over 900 gene mutations 
causing CF has been identified (The Cystic Fibrosis Genetic Analysis 
Consortium, CFGAC: http://www.genet.sickkids.on.ca/cftr). CF 
patients have abnormal sodium and chloride transport mechanisms 
causing disturbances in the mucus production forming and mucus 
transporting on the ciliated respiratory epithelium. A dehydrated 
thickened viscous mucus impairs mucociliary clearance (Deane and 
Schwartz 1997). The typical clinical features for CF patients are an 
abnormally high concentration of chloride in the sweat, lung and 
paranasal infections, nasal polyposis, pancreatic insufficiency, male 
infertility and decreased female fertility (Aitken and Fiel 1993). As 
many as 10% of children with CF may have concomitant nasal polyps 
(Maran and Lund 1990). Adult patients with CF have even higher 
frequencies of nasal polyps, reported to be 20-48% (di Sant’ Agnese 
and Davis 1979, Aitken and Fiel 1993).  
 
 
2.2.3. Nasal polyps, asthma and ASA intolerance  
 
Although nasal polyposis seems to be partially related to infection 
(characterised by neutrophilic-lymfocytic inflammation), it is mainly 
related to the eosinophilic inflammatory mechanism as in ASA 
intolerance or asthma (Holopainen et al. 1979, Settipane 1996). 
Asthma is found in about one-third of adults with polyps (Drake-Lee 
et al. 1984b) and 7% of patients with asthma have nasal polyps 
(Settipane and Chafee 1977).  
 
Some 15-36% of patients with nasal polyps suffer from ASA 
intolerance (Chafee and Settipane 1974, Schapowal et al. 1995) and up 
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to 60% of patients with ASA intolerance have nasal polyps (Maran 
and Lund 1990). The triad of nasal polyps, ASA intolerance and 
asthma was first described by Widal, Abrami and Lermoyez in 1922. 
This association was later emphasised by Samter (Samter and Beers 
1967). The classic triad occurs in approximately 8-39% of all polyp 
cases (Drake-Lee 1987, Maran and Lund 1990).  
 
In Finland the prevalence of nasal polyposis is 16.5% in asthmatic 
patients and the prevalence of the triad nasal polyposis, ASA 
intolerance and asthma is 4.3% in patients with asthma (Hedman et al. 
1999). A hereditary factor has been considered to be involved in the 
development of nasal polyps (Settipane and Pudupakkam 1975, 
Greisner and Settipane 1996).  
 
 
2.3. CLINICAL PICTURE AND DIAGNOSIS 
 
2.3.1. Clinical symptoms and complications 
 
Nasal polyps are usually bilateral multiple and freely movable 
protrusions of benign oedematous mucosa. They are glistening, pale-
grey smooth and semitranslucent in appearance. Polypoid lesions are 
mainly situated in the middle meatus and most of the polyps originate 
from the mucosa of the ostia, anterior and posterior ethmoidal clefts 
and frontal and sphenoethmoidal recesses but also from middle 
turbinate and septum (Larsen and Tos 1991, Larsen and Tos 1996). 
Polyps may occur in all paranasal sinuses, too (Drake-Lee 1987). 
Polyps visible in the middle meatus usually originate from the mucosa 
of the ostia, anterior ethmoidal cleft or frontal recess but polyps visible 
between the nasal septum and the middle or the superior turbinates 
either originate from the olfactory ridge, posterior ethmoidal cleft or 
sphenoethmoidal recess (Larsen and Tos 1991, Larsen and Tos 1996, 
Stammberger 1997). Antrochoanal polyps arise in the maxillary 
antrum and prolapse through the ostium of the sinus in the middle 
meatus. They are seen in the nose or, if larger, in the posterior choana 
(Drake-Lee 1987). Most frequently nasal polyps are found on the 
concave site of the deviated septum (Maran and Lund 1990).  
 
Clinically nasal polyposis is characterised by oedematous masses in 
the nasal and paranasal cavities, leading to nasal obstruction, retention 
of nasal and sinus secretion, loss of smell, headache, and reduced 
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general well-being (Bachert et al. 1998). When nasal obstruction 
becomes total, the patient gets symptoms of secondary sinusitis, and 
even anatomical changes, with a widening of the bridge of the nose. 
Over 80% have secondary sinusitis and with it, there may be an 
associated cough and bouts of acute sinusitis. (Maran and Lund 1990). 
The relationship between polyps and sinusitis is critical and the 
presence of inflammation may be a strong trigger for polyp disease. 
Nasal polyps can produce a wide range of radiological changes. The 
commonest is generalised bilateral loss of translucence in all sinuses, 
but in addition, 20% of patients show evidence of ethmoidal 
expansion called the ”remodelling”- phenomenon (Maran and Lund 
1990, Som et al. 1991). 
 
In aggressive paranasal and nasal polyposis, erosion of ethmoid bones, 
walls of the sphenoid sinuses and the floor of the anterior cranial fossa 
and other sinus walls can happen resulting in consequent 
ophthalmologic and neurologic sequeale even blindness (Winestock et 
al. 1978, Rejowski et al. 1982, Som et al. 1991). It has been suggested 
that probably obstruction of the ostia by polypoid degeneration can 
also result in a mucocele (Finn et al. 1981), which is an encapsulated 
mucous-filled mass lined with a low columnar or cuboidal epithelium, 
containing occasional goblet cells. The mucoperiosteal lining of the 
sinus becomes widened, with dense connective tissue of varying 
thickness supporting the epithelial lining (Schuknecht and Lindsay 
1949).  
 
 
2.3.1.1. Recurrence of nasal polyps 
 
There are few reports on the clinical course and recurrence of nasal 
polyps. In the study published by Blumstein and Tuft (1957) 
recurrence of polyposis after repolypectomy and allergy management 
was found in 53% of cases during a follow-up for 4.3 years. Some of 
those patients with recurrent polyps were followed for 5 to 7 years. 
This follow-up study showed that the patients with the highest 
recurrence of nasal polyps had a high incidence of asthma and no 
specific etiology with negative skin reactions while the patients with 
identifiable and controllable allergies had the lowest recurrence of 
polyps. Larsen and Tos described the clinical course of primary nasal 
polyposis in 1994, the follow-up time being 1 to 8 years (median 57 
months). They found that patients with asthma, acute recurrent or 
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chronic sinusitis, ASA intolerance or atopic allergy required more 
polypectomies and more topical steroid treatment than patients 
without these conditions. In another study of nasal polyp patients 
followed for approximately 8 years (38-145 months) after simple 
polypectomies Larsen and Tos (1997) found that ASA intolerant 
patients had the highest number of polypectomies and patients with 
asthma had more polypectomies than those without them. Jäntti-
Alanko et al. (1985) described a 4-year follow-up study of patients 
with nasal polyps, and in that study the frequency of re-operations was 
significantly higher and the use of topical corticosteroid treatment 
more frequent among patients with ASA intolerance than patients 
without ASA-intolerance. It is commonly thought that recurrence and 
activity of nasal polyposis diminish with time but studies with long 
enough follow-up periods to confirm this have not been published. 
 
 
2.3.1.2. Loss of the sense of smell 
 
Diminished olfactory function is a common complaint in patients with 
nasal polyposis. The disorders of olfaction have been described as 
conductive or sensorineural. (Ophir et al. 1986). A diminished sense 
of smell associated with chronic rhinosinusitis with or without nasal 
polyposis is thought to be predominantly conductive, a result of 
mucosal obstruction to airflow through the superior nasal meatus 
(Hosemann et al. 1993). It has been shown that increases in the size of 
compartments of the nasal cavity around the olfactory cleft generally 
increase olfactory ability (Hornung and Leopold 1999). Also the 
association between nasal allergy and a loss or diminution of smell has 
been noted frequently in the literature (Fein et al. 1966, Cowart et al. 
1993, Apter et al. 1995). Olfactory thresholds are also known to be 
related to age being markedly higher among elderly people (Doty et al. 
1984, Simola and Malmberg 1998), which must be taken into 
consideration when studying sense of smell among elderly patients. 
 
It has been shown that past history of recurrent polyp operations is 
associated with poorer smell test results in chronic rhinitis patients 
(Simola and Malmberg 1998). Hosemann et al. (1993) found that 87% 
of those patients for whom ethmoidal surgery did not improve the 
hyposmia or anosmia had already earlier had surgical interventions to 
their paranasal sinuses.  
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Olfactory disturbances occur also in nasal infections, sometimes even 
irreversible anosmia can follow. It has been shown in a biopsy study, 
that chronic nasal infection may damage areas of the olfactory organ 
and this will be replaced with respiratory epithelium (Douek et al. 
1975). In a study of Kern (2000) 30 patients underwent olfactory 
biopsy at the time of surgery with evaluation by a pathologist. 
Nineteen of these 30 patients had olfactory mucosa in the biopsy 
specimen, the rest had only respiratory or indeterminate mucosa. Ten 
patients had pathological changes in the olfactory mucosa with an 
influx of lymphocytes, macrophages, and eosinophils and 7 of these 
ten had olfactory deficits as determined by the University of 
Pennsylvania Smell Identification Test (UPSIT). Nine patients had 
normal olfactory mucosa and normal olfactory function. Infections are 
usual complications in chronic polyposis, and some effects on the 
olfactory sense may also be due to these kinds of sensorineural 
mechanisms. However the methods used for smell identification for 
measuring olfactory threshold do not distinguish between a 
sensorineural and a conductive defect.  
 
 
2.3.2. The diagnosis of nasal polyps 
 
2.3.2.1. Clinical examination 
 
The diagnosis of massive intranasal polyposis associated with 
subjective nasal congestion is not difficult. Simple anterior rhinoscopy 
reveals such polyps easily. Antrochoanal polyps can also been seen in 
posterior rhinoscopy. Smaller polyps limited to the middle meatus 
including ethmoidal bulla, frontal recess, and uncinate process are 
more difficult to see, but they can often reliably be identified 
endoscopically (Penttilä et al. 1990). 
 
 
2.3.2.2 Imaging techniques 
 
Polypoid masses in the paranasal sinuses can be diagnosed by x-ray, 
sinus computed tomography (CT) scanning, magnetic resonance 
imaging (MRI) or ultrasound (US). The commonest finding in x-ray is 
generalised bilateral loss of translucence in all sinuses (Maran and 
Lund 1990). It is not radiologically possible to establish the true nature 
of an opaque sinus, i.e., if it is a fluid, (polypoid) mucous membrane 
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thickening, cyst or tumour. Axelsson et al. (1970) demonstrated 
secretions by irrigation in 86% of the completely opaque maxillary 
sinuses in x-ray and in 60% of cases with mucous membrane 
thickening. In the latter cases discharge was demonstrated by x-ray in 
24% when four standard projections were used.  
 
A-mode ultrasound (A-US) is a simple, non-invasive and non-ionising 
method for detecting fluid or even mucosal swelling in inflamed 
maxillary and frontal sinuses. A-US is based on the principle that 
reflection of US occurs at the boundary of two media with differing 
acoustic impedances (acoustic impedance = density of the medium x 
sound velocity in the medium). The boundary of two soft tissues 
reflects less than 10%, the boundary between soft tissue and bone 
reflects 50-70% and air acts as a total reflector. A sinus filled with 
secretion or a cyst or a loose polypoid mucosal thickenings causes a 
strong echo from the bony back wall (Revonta 1980).  
 
To avoid repeated exposure to ionising radiation, A-US is widely used 
in diagnosing sinusitis in health centres and hospitals in the 
Scandinavian countries and in Finnish primary care. A-US has been 
shown to be quite reliable in the diagnosis of acute maxillary sinusitis 
with fluid retention (Mann et al. 1977, Revonta 1979, Puhakka et al. 
2000) but controversy still exists over the reliability of A-US in 
detecting fluid retention or mucosal swelling in patients suffering from 
chronic rhinosinusitis (Mann et al. 1977, Druce et al. 1988) and in 
detecting mucosal swelling or polyps/cysts in patients with acute 
maxillary sinusitis (Revonta 1980, Jensen and von Sydow 1987). 
Slight or moderate mucosal thickenings have been distinguishable 
from retained secretion, but large cysts/polypoid swellings of the 
mucosa produced a finding indistinguishable from retained secretion 
in a study by Revonta (1980). There are however studies with poor 
correlation. Using A-US and x-ray to evaluate antral mucosal 
thickening in chronic sinusitis, Druce et al. (1988) found the total 
specificity to be 61% and the sensitivity 34%. In a study by Jensen and 
von Sydow (1987) the A-US findings of mucosal thickening without 
fluid correlated with x-ray in only 19% and different degrees of 
mucosal thickening were poorly demonstrable. These contradictory A-
US results indicate that further studies are needed. There are probably 
patients in whom A-US is not a suitable tool for diagnosing fluid level 
or mucosal thickening.  
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The A-mode technique is increasingly being substituted by B-mode 
ultrasound (B-US) used by radiologists. B-US provides two-
dimensional information about the structures examined, but there are 
few studies concerning B-US and paranasal sinuses. In a study by 
Tiejden et al. (1998) 78 patients were examined by CT and 
subsequently by B-US, two-thirds before endonasal surgery and one-
third for diagnosis of serious facial pain and swelling. Eighty-three of 
114 pathological maxillary sinus findings in CT could also be 
diagnosed by B-US (sensitivity 72.8%). Except for circumscribed 
polyps and moderate general swelling of the mucosa, the detection rate 
by US sonography was 97.4% for maxillary sinuses.  
 
Sinus CT is currently the modality of ionising choice in the evaluation 
of the paranasal sinuses and adjacent structures. Its ability to optimally 
display bone, soft tissue, and air facilitates accurate depiction of the 
anatomy and extent of disease in and around the paranasal sinuses 
(Zinreich 1990, Zinreich 1992). 
 
Non-ionising MRI can be also used but it is still often unattainable for 
economic reasons. MRI has superseded CT in resolving soft tissue 
structures and is superior in distinguishing between bacterial and 
fungal sinusitis as well as inflammation and neoplasm, its use for the 
evaluation of nasal anatomy, particularly for the ethmoid sinuses, is 
precluded because of its poor resolution of bone (Zinreich 1992). 
 
 
2.3.3. Histological findings 
 
Nasal polyps are characterised by a pseudostratified ciliated columnar 
epithelium, thickening of the epithelial basement membrane, few 
blood vessels and nerve endings (Frenkiel and Small 1991). In general, 
the stroma of nasal polyps is oedematous, which may be the result of a 
leakage of plasma through open endothelial junctions in the blood 
vessels (Cauna 1972). The stroma regularly contains eosinophils, 
neutrophils, lymphocytes, monocytes, plasma cells, mast cells and 
macrophages. The vascularisation is poor and lacks vasoconstrictor 
innervation, with the exception of the nerve terminals in the pedicle of 
polyp. Mast cells occur about twice as frequently in nasal polyps as in 
the normal nasal respiratory mucosa and the mast cell granules of 
polyps are relatively small and they either lack the outer lamellar 
element or are largely degranulated (Cauna 1972). Tissue eosinophilia 
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is a general character of nasal polyps and is found in 80-90% of all 
cases (Settipane 1996, Drake-Lee 1987). In antrochoanal polyps 
eosinophilia can be found in 20-65% of cases (Heck et al. 1950, Min 
et al. 1995). Mucus glands almost never can be found in antrochoanal 
polyps but frequently in nasal polyps (Heck et al. 1950). One way to 
classify polyps is a subdivision into four histological different types 
according Hellquist, which sometimes can be essential due to the 
differential diagnosis of neoplastic disease (Hellquist 1996).  
 
 
2.3.3.1. Oedematous, eosinophilic polyp 
 
The predominant histological finding is an oedematous, eosinophilic 
type of inflammation, with an incidence rate of 86% of sinonasal 
polyps (Davidsson and Hellquist 1993). In this kind of polyp the 
histological hallmarks comprise oedematous stroma, often hyperplasia 
of the seromucous glands, numerous eosinophils and mast cells and 
thickened basement membrane (Hellquist 1996).  
 
 
2.3.3.2. Other types of polyps  
 
For the chronic inflammatory polyp the lack of stromal oedema and 
goblet cell hyperplasia are the most striking features. Goblet cells are 
present but the epithelium is devoid of goblet cell hyperplasia. The 
epithelium frequently shows squamous and cuboidal metaplasia 
(Hellquist 1996). This fibro-inflammatory neutrophil type represents 
less than 10% of sinonasal polyps (Davidsson and Hellquist 1993). 
This histological type is often found in CF, primary ciliary dyskinesia 
(PCD) syndrome or Young’s syndrome (Settipane 1996).  
 
The third type of polyp is a polyp with hyperplasia of seromucinous 
glands (Hellquist 1996). This polyp type can be misdiagnosed as an 
adenoma (Friedmann and Osborn 1982). This type of nasal polyp is 
rare and represents less than 5% of sinonasal polyps (Davidsson and 
Hellquist 1993). 
 
The fourth type polyp with stromal atypia is very rare and it has 
distinct histological features. The main feature, which distinguishes a 
polyp with atypical stroma from a neoplasm, is a lack of mitoses 
(Hellquist 1996). 
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2.3.4. Differential diagnosis  
 
Initially polyps were thought to be of neoplastic origin (Drake-Lee 
1987). In the presence of nasal polyps other considerations should also 
taken into account, namely tumours (e.g. inverted papilloma, juvenile 
nasopharyngeal angiofibroma, esthesioneuroblastoma, carcinoma, 
sarcoma, melanoma, meningioma and glioma (in the newborn)) and 
meningoencephalocele especially in children. 
 
 
2.4. ETIOLOGY OF NASAL POLYPS 
 
The etiology of nasal polyposis is mainly unknown although it has 
been connected with many disease states. Different inflammatory 
factors, e.g. viral upper respiratory infections, allergic rhinitis and 
various functional disturbances of the mucous membrane have been 
reported to be predisposing factors leading to sinusitis (Gungor and 
Corey 1997). 
 
 
2.4. 1. Allergy 
 
Because of the high concentration of eosinophils within polyps, the 
popular concept was that all nasal polyps were associated with 
allergies in the 1930s (Kern and Schenk 1933). Many attempts were 
made to link nasal polyps to allergens, but this concept was rejected by 
most physicians in the 1970s and 1980s when investigators were 
unable to demonstrate an allergy linkage. Numerous publications have 
shown that there is no higher incidence of allergies and no elevated 
rates of positive allergy skin tests in the patients with nasal polyps 
(Caplin et al. 1971, Settipane and Chafee 1977, Perkins et al. 1989). 
However even in recent years an immunoglobulin E (IgE)-mediated 
mechanism and elevated incidences of allergies have been reported for 
a small subgroup of patients with nasal polyps (Sin et al. 1997). 
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2.4.2. Infections 
 
Many patients with nasal polyps have secondary chronic sinusitis 
(Maran and Lund 1990). Blockage of the sinus ostia appears to begin 
the series of events leading to chronic sinusitis (Gwaltney et al. 1995).  
 
 
2.4.2.1. Virus infection  
 
Weille (1966) suggested that polyps are caused by viral infection. 
Kozak et al. (1991) had a hypothesis for the viral etiology of nasal 
polyps including the following steps: viral infection, inflammatory 
response, persistence of the virus, persistent antigenic stimulation, 
nasal polyposis. They studied the role of viruses by hybridisation tests 
for deoxyribonucleic acid (DNA) of some infectious agents in nasal 
polyps but the tests were negative. They stated that the absence of 
virus in the tissue supported their hypothesis that viral involvement in 
nasal polyps is an early event. 
 
 
2.4.2.2. Bacterial infection  
 
Chronic sinusitis is a common disease with patients of nasal polyposis 
and thus purulent infection might be an important factor in the 
etiology of nasal polyps. In rabbits polyps have been shown to develop 
in the sinus mucosa in three weeks after artificial infection by 
pneumococci. No polyps developed on the contralateral, non-infected 
maxillary sinus in those 6 animals (Norlander et al. 1993). Polyps can 
then have an inflammatory origin with the predominant cells being 
lymphocytes and neutrophils. Antrochoanal polyps have been 
associated with inflammatory disease (Min et al. 1995). Many kinds of 
diseases also can contribute to this situation. In these cases the 
diagnoses to be considered are CF and PCD syndrome. However these 
diseases are not primarily infective; in these conditions, infection 
arises secondary to the defect in the mucosal defence (Mackay and 
Cole 1987). 
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2.4.2.3. Fungal infection  
 
Allergic fungal sinusitis (AFS) is a newly appreciated diagnosis. In 
1971, McCarthy and Pepys observed that 10% of patients with allergic 
bronchopulmonary aspergillosis complained of producing nasal plugs 
similar to those expectorated from the bronchi. In that study 41.4% 
(46/111) had maxillary sinusitis as shown on x-ray films. Aspergillus 
fumigatus grew in cultures of the nasal plug and sinus lavages. 
Katzenstein et al. (1983) described the case histories of seven 
otherwise healthy patients with asthma, nasal polyposis, sinusitis and a 
unique ”allergic mucin” within sinuses. This allergic mucin contained 
laminated mucin, eosinophils, Charcot-Leyden crystals, and fungal 
hyphae. This condition was called ”allergic aspergillus sinusitis”. With 
heightened awareness of the disease, an increased number of reports 
have been published recently. The common diagnostic criteria for 
allergic fungal sinusitis are (1) chronic rhinosinusitis, (2) the presence 
of allergic mucin (clusters of eosinophils and their by-products, e.g., 
Charcot-Leyden crystals and major basic protein (MBP)), and (3) the 
presence of fungal organisms within that mucin, confirmed by 
histology, culture or both (Cody et al 1994, deShazo and Swain 1995, 
Ramadan and Quraishi 1997). In a study of 210 consecutive chronic 
rhinosinusitis patients with or without polyps, fungal cultures of nasal 
secretions were positive in 202 (96%) patients and in 100% (14/14) of 
control patients (Ponikau et al. 1999). In that study during the 
culturing of nasal secretions, fungi had to be extracted from the mucus 
before being placed on the growth medium. The minimum incubation 
time of 30 days seemed necessary for complete recovery. They 
proposed the term eosinophilic fungal rhinosinusitis instead of AFS 
because IgE-mediated hypersensitivity to fungal allergens was not 
evident in the majority of AFS patients.  
 
 
2.4.3. Diseases associated to nasal polyps 
 
2.4.3.1. Samter’s triad 
 
Samter’s triad or ASA triad is the syndrome of nasal polyposis, 
asthma and ASA intolerance, which was first described by Widal et al. 
in 1922. Samter and Beers (1967) clarified the relationship later. The 
most plausible basic mechanism underlying sensitivity to aspirin is 
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that inhibition of cyclooxygenase by aspirin and other cyclooxygenase 
inhibitors could divert the metabolism of arachidonic acid from the 
cyclooxygenase pathway to lipoxygenase pathway, thereby increasing 
the generation of leukotrienes (LTs) by removing prostaglandin E2 
(PGE2) a dominant cyclooxygenase product of airways, which has an 
inhibitory effect on inflammatory cells and pathways (Szczeklik 
1990). Patients tend to exhibit ”panmucosal” reactivity with reactive 
mucosa throughout the airway including the traceobronchial tree and 
sinuses. The sinus disease is frequently extensive, but can be managed 
with aggressive medical and surgical therapy. This triad has been 
found in 8-39% of patients with nasal polyps (Drake-Lee 1987, Maran 
and Lund 1990, Schapowal et al. 1995) 
 
 
2.4.3.2. Cystic fibrosis 
 
Cystic fibrosis (CF) is one of the most frequent hereditary diseases 
found in Caucasians and it is caused by an autosomal-recessive defect 
of the CFTR gene on chromosome 7 (coding for a chloride channel) 
(Kerem et al. 1989, Riordan et al. 1989, Rommens et al. 1989). To 
date, some 900 gene mutations causing CF has been identified (The 
Cystic Fibrosis Genetic Analysis Consortium, CFGAC: 
http://www.genet.sickkids.on.ca/cftr). The F508 mutation is the most 
common one (Estivill et al. 1997), but the frequency of mutations 
greatly varies between different populations. The frequency of F508 
is found to be 65-80% in North American, British, Swiss and Dutch 
patients but only 51-58% in Spanish and Italian populations and 37% 
of black American patients (Deane and Schwartz 1997). The incidence 
of CF in Finland, 1:26500 new-borns, is one of the lowest in 
Caucasian populations (European Working Group for Cystic Fibrosis 
Genetics 1990) (Kere et al.1994). In Finland the incidence of CF is 
approximately one tenth that in other European countries, including 
the neighbouring countries of Sweden, Denmark, the former Soviet 
Union and Norway (Kere et al. 1989). The carrier incidence of CF 
varies in different populations. In Finland where CF is uncommon one 
in 80 is a carrier of the gene (Kere et al. 1989) but for example in the 
USA one in 25 Caucasians is a carrier of a gene mutation (Aitken and 
Fiel 1993).  
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The rarity of CF in Finland has been explained by genetic drift (Kere 
et al. 1989). The most common F508 mutation (Estivill et al. 1997) 
accounts for 45% of CF chromosomes and 394delTT mutation 30% of 
CF chromosomes in Finland (Kere et al. 1990, Kere et al. 1994). 
394delTT is a specific Nordic mutation and this mutation is rare 
outside the Nordic countries (Kere et al.1994, Schwartz et al. 1994). 
 
This defect causes abnormal transepithelial chloride transport across 
the respiratory and exocrine gland cell epithelium and impaired 
mucociliary clearance (Deane and Schwartz 1997). The typical clinical 
features for CF patients are an abnormally high concentration of 
chloride in the sweat, lung and paranasal infections, nasal polyposis, 
pancreatic insufficiency, male infertility and decreased female fertility 
(Aitken and Fiel 1993). However, the clinical expression of the states 
associated with the mutations is wide. 
 
As many as 10% of children with CF may have concomitant nasal 
polyps (Maran and Lund 1990). Adult patients with CF have higher 
frequency of nasal polyps, reported to be 20-48% (di Sant’ Agnese and 
Davis 1979, Aitken and Fiel 1993).  
 
There are some reports in which the prevalence of CF mutations has 
been higher in infectious patients than in the average population. An 
abnormal distribution of CF heterozygotes was found in chronic 
bronchial hypersecretion (Dumur et al. 1990). Wang et al. (1998) 
found a higher frequency of CF mutation carriers among chronic 
sinusitis patients than in a normal control group. A recent study 
showed that in non-alcoholic pancreatitis the CF mutations are more 
common than in population on average (Sharer et al. 1998). 
 
However, there are reports in which the CF frequency has not been 
increased. The prevalence of F508 mutation has been studied among 
17 patients diagnosed with diffuse panbronchiolitis, but no mutation 
was found among them (Akai et al. 1992). In a study with severe nasal 
polyposis patients CF mutations were not detected to have an 
inactivation of the CFTR gene (Irving et al. 1997). The frequency was 
not increased among chronic bronchitis patients (Artlich et al. 1995). 
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2.4.3.3. Primary ciliary dyskinesia syndrome 
 
The incidence of the autosomal recessive disorder, primary ciliary 
dyskinesia (PCD) syndrome, is estimated as being between 1 in 15000 
to 30000 persons (Rott 1983). Patients with PCD syndrome are known 
to suffer from the presence of nasal secretions since the first day of life 
and this leads to recurrent upper respiratory tract infections with 
chronic sinusitis and nasal polyps up to 40% of them. Chronic and 
recurrent ear problems are found in up to 100% of the children 
(Pedersen and Mygind 1982). These are due to malfunction of the 
cilia, which is caused by a lack of dynein in microtubules sometimes 
even in 100% of cilia (Chao et al. 1982). The maximal manifestation 
of the illness, known as Kartagener’s syndrome is characterised by 
chronic rhinosinusitis, chronic bronchitis with bronchiectasis and situs 
inversus, (Pedersen and Mygind 1982, Afzelius 1986). Male infertility 
is typical, but not 100% (Munro et al. 1994). 
 
 
2.4.3.4. Churg-Strauss syndrome 
 
Churg-Strauss syndrome is classified as a granulomatous vasculitis. It 
is characterised by the presence of a history of atopy, asthma, and 
eosinophilia in conjunction with a systemic necrotizing vasculitis. 
(Churg and Strauss 1951). In a study by Olsen et al. (1980) 69% 
(22/32) of Churg-Strauss syndrome patients had nasal manifestation 
and nasal polyps were seen in 11 of 32 patients (34%). 
Histopathologically, polyps removed from the nose show necrosis in 
association with eosinophilic exudate, severe fibrinoid collagen 
alteration, and granuloma formation with accumulation of epithelioid 
and giant cells that are called allergic granuloma (Mc Donald 1993). 
 
 
2.4.3.5 Young’s syndrome  
 
This syndrome is characterised by recurrent respiratory diseases, 
azoospermia and nasal polyposis and it was first described from the 
north of England by Young in 1970 (Young 1970). The respiratory 
disease consists of severe chronic sinusitis, which may be associated 
with bronchiectasis. CF can be excluded because the patients have 
normal sweat chloride tests and pancreatic function. Their ciliary ultra 
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structure is normal (Frenkiel and Small 1991). The azoospermia in 
Young’s syndrome is due to a blockage in the epididymis that is 
distinguishable from the defect in the vas deferens associated with CF. 
The patients have normal spermatogenesis. The prevalence of Young’s 
syndrome is considerably higher than that of CF or Kartagener’s 
syndrome. Only a few cases of Young’s syndrome have been reported 
in the USA (Schanker et al. 1985, Hughes et al. 1987), but the 
incidence is remarkable higher in the United Kingdom (Hendry et al. 
1993). It is responsible for 7.4% of cases of male infertility (Settipane 
1996). 
 
 
2.4.3.6. Nonallergic rhinitis with eosinophilia syndrome  
 
Nonallergic rhinitis with eosinophilia syndrome (NARES) is a new 
entity and it was briefly described in 1979 by Jacobs, Freedman and 
Boswell. It was analysed in 1980 by Mullarkey, and in 1981 by Jacobs 
(Mullarkey et al. 1980, Jacobs et al. 1981). Patients with NARES have 
significant nasal eosinofilia but no evidence of allergic disease by 
history, physical examination, skin tests, or serum IgE levels. This 
syndrome is of special relevance because of the inflammatory 
functions of the eosinophils (Venge et al. 1987), the frequency of nasal 
polyps, possibly being a precursor of the triad of nasal polyposis, 
nonallergic asthma, and ASA intolerance (Samter and Beers 1968, 
Monoret-Vautrin et al. 1990). Twenty-nine percent of patients 
suffering from NARES had nasal polyps in a study by Monoret-
Vautrin et al. (1990).  
 
 
2.5. PATHOGENESIS OF NASAL POLYPS  
 
The pathogenesis of nasal polyps is not clear. Many theories have been 
presented. Bernstein et al. found alterations of the bioelectricity of 
sodium and chloride channels in the nasal mucosa (Bernstein et al. 
1995, Bernstein et al. 1997). They studied polyp and turbinate mucosa 
using histochemical and immunohistochemical methods. The samples 
were treated with protease to achieve disaggregation of the epithelial 
cells. Those cells were cultured on permeable collagen matrix 
supports. At the time of maximal transepithelial potential difference, 
the epithelial cells were mounted in modified Ussing chambers and 
exposed to a sodium-positive channel blocker (amiloride 
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hydrochloride) and to selected chloride-negative channel agonists 
(isoproterenol bitartrate and adenosine triphosphate). Epithelial cells 
obtained from the polyps exhibited higher transepithelial potential 
differences and equivalent short-circuit currents than turbinate 
cultures. The responses to amiloride, isoproterenol and adenosine 
triphosphate were also greater for polyp than for turbinate cultures. 
The following theory was proposed. Local release of inflammatory 
mediators could cause sodium absorption and chloride permeability to 
be higher in polyps than in turbinate epithelia. Increased sodium 
absorption may result in an increased movement of water into the cell 
and into the interstitial fluid. The resultant oedema may lead to growth 
and enlargement of the polyp (Bernstein et al. 1995).  
 
Vasomotor imbalance is implied because the majority of patients with 
nasal polyps are not atopic and no obvious allergen can be found. 
Patients have often a prodromal period of rhinitis prior to occurrence 
of polyps (Drake-Lee 1987).  
 
Formation of nasal polyps has been suggested to involve a rupture of 
the surface epithelium and the prolapse of the lamina propria to be the 
result of tissue pressure from an oedematous and infiltrated nasal 
mucosa (Tos and Mogensen 1977). 
 
 
2.5.1. Chemical mediators 
 
Numerous mediators have been found in nasal polyps. Cytokines, 
adhesion molecules and growth factors have been the main interest of 
research. Histamine, serotonin, LTs, norepinephrine, kinins, esterase, 
and possibly PGD2 are found within polyp stroma (Settipane 1987) 
and also increased levels of IgA and IgE within nasal polyps (Chandra 
and Abrol 1974, Holopainen et al. 1979, Drake-Lee 1987). Rasp et al. 
(1999) found significantly increased levels of IgE in the nasal 
secretions of nonallergic patients suffering from nasal polyposis 
compared to controls. These levels were as high as IgE levels in the 
nasal secretion of allergic patients without nasal polyps. Histamine, in 
comparison to serum levels, has been found in 100- to 1000-fold 
concentrations within nasal polyps (Drake-Lee 1987). Inducible nitrid 
oxide synthesis expression is upregulated in nasal polyp disease and 
inducible nitrid oxide synthesis is localised in the polyp epithelial 
layer (Watkins et al. 1998). 
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2.5.1.1. Cytokines 
 
2.5.1.1.1. Interleukins 
 
Interleukins (ILs) are a family of mediators released by many 
inflammatory and non-inflammatory cells. In nasal polyps IL-1 is 
regularly found (Simon 1996) and it is found primarily in monocytes 
and to a lesser extent in polymorphonuclear cells (Liu et al. 1993). IL-
2 may have involvement in nasal polyps because there are findings 
that nasal polyp mast cells are IL-2 receptor positive (Larocca et al. 
1989). IL-3 has either not been found at all or only intermittently at 
low concentrations in some studies (Simon 1996, Bachert et al. 1997), 
but in other studies IL-3 has regularly been found in polyp stroma 
(Hamilos et al. 1995). IL-4 has been localised in eosinophils in nasal 
polyps (Nonaka et al. 1995). IL-5 plays a key role in eosinophilia and 
eosinophils are the only human leukocytes expressing receptors 
specific for IL-5 (Migita et al. 1991). IL-5 concentration in the nasal 
secretion of non-allergic patients suffering from nasal polyps reaches 
similar levels as in allergic patients without nasal polyps and these 
levels are significantly higher than those of controls (Rasp et al. 1999). 
IL-8 has been found in polyp mucosa but it is also found in normal 
nasal mucosa (Simon 1996). In vitro nasal epithelial cells, in some 
conditions can release IL-6 (Ohtoshi et al. 1991), but concentrations of 
IL-6 and IL-10 in patients suffering from nasal polyps did not differ 
from controls (Bachert et al. 1997). IL-13 messenger ribonucleic acid 
(mRNA) levels increase in nasal mucosa after a grass pollen allergen 
provocation (KleinJan et al. 1999). 
 
 
2.5.1.1.2. RANTES  
 
The concentration of a cytokine called RANTES (regulated upon 
activation, normal T-cell expressed and secreted) in polyp stroma has 
also been subject to contradictory findings. It has strong eosinophil 
chemotactic and activating effects (Rot et al. 1992, Alam et al. 1993). 
Some studies have regularly detected RANTES within polyp stroma 
(Beck et al. 1996, Teran et al. 1997), or even found increased levels of 
RANTES mRNA and protein (Hamilos et al. 1997, Allen et al. 1998), 
but others could not detect any differences with the controls (Bachert 
et al. 1997).  
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2.5.1.2. Adhesion molecules 
 
Increased levels of VCAM-1 (vascular cell adhesion molecule 1) are 
found in nasal polyps (Beck et al. 1996, Hamilos et al. 1996). VCAM-
1 is an endothelial surface molecule important for the adhesion of 
eosinophils to the endothelium (Jordana and Dolovich 1997). 
 
 
2.5.1.3. Growth factors 
 
2.5.1.3.1. IGF-1, TGF-  
 
In recent years, several studies have drawn attention to growth factors 
in nasal polyps (Petruson et al. 1988, Ohno et al. 1992, Pyykkö et al. 
1998). Petruson et al. (1988) found that nasal polyps from 15 patients 
expressed insulinlike growth factor I (IGF-I) immunoreactivity. Ohno 
et al. -specific 
mRNA in nasal polyps, as well as in the nasal mucosa from a patient 
with allergic rhinitis, but it has not been found in normal mucosa. 
d to play a 
central role in the pathogenesis of chronic inflammation and fibrosis. 
Basic fibroblast growth factor (bFGF) is a potent growth factor for 
angiogenesis, wound healing, thickening of epithelial membrane, 
fibrosis and epithelial and glandular hyperplasia (Pyykkö et al. 1998). 
In a study by Pyykkö et al. (1998) polyps and for comparison also 
saliva and rhinorrhea were assayed with commercially available 
ELISA (enzyme-linked immunosorbent assay) and all the nasal polyps 
showed high concentration of bFGF but human saliva only had small 
concentrations and it was barely detectable in patients with rhinorrhea. 
 
 
2.5.1.3.2. Vascular endothelial growth factor 
 
The gene code encoding vascular permeability/vascular endothelial 
growth factor (VPF/VEGF) and the genes encoding its receptors 
(kinase domain region (KDR) receptor and fms-like-tyrosine kinase -1 
(flt-1) receptor) have been extensively analysed for angiogenesis and 
vascular permeability (Ferrara and Davis-Smyth 1997). On a molar 
basis, VPF/VEGF is known to be more potent than histamine in the 
induction of vascular hyperpermeability (Senger et al. 1983). Ito et al. 
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(1995) examined polyps using Northern blotting and found that all 
nasal polyps from four patients expressed VPF/VEGF and KDR 
mRNAs. Their in situ hybridisation experiments suggested that plasma 
cells are active in the synthesis of VPF/VEGF (Ito et al 1995). 
VPF/VEGF has also been found in mast cells in some studies but not 
from nasal polyps (Boesiger et al. 1998, Grützkau et al. 1998, Yamada 
et al. 1998). Thus, previous studies suggest that VPF/VEGF may be 
involved in the pathogenesis of nasal polyposis.  
 
 
2.5.1.4. Cytology and cytological markers 
 
2.5.1.4.1. Eosinophilia 
 
Eosinophils are the main characteristic inflammatory cells of nasal 
polyps and they are found in 80-90% of all polyps (Drake-Lee 1987, 
Settipane 1996). Neutrophils predominate in polyps in patients with 
CF, PCD and Young’s syndrome (Settipane 1996). The correlation 
between the degree of eosinophilia and the glucocorticoid response is 
linked to glucocorticoid receptors on the human eosinophils (Prin et 
al. 1989). On activation, eosinophils release inflammatory products 
from their granules, e.g. MBP, eosinophil cationic protein (ECP), 
eosinophil peroxidase (EPO), LTs and platelet activating factor (PAF). 
When released, these products directly damage the epithelium of the 
upper and lower respiratory tract (Gleich et al. 1988, Harlin et al. 
1988). Activated, degranulated eosinophils predominate in polyp 
stroma (Appenroth et al. 1998) and may contribute to the tissue 
damage resulting in polyp formation. 
 
 
2.5.1.4.2. Mast cells 
 
Mast cells are widely distributed in the connective tissues of mammals 
and other vertebrates, where they are frequently located in close 
proximity to blood vessels (Selye 1965, Galli et al. 1994). They have a 
well-established role in the immediate hypersensitivity reaction and 
chronic inflammation, but otherwise their functions are mysterious 
(Yamada et al. 1998). It has earlier been shown that mast cells occur 
about twice as frequently in nasal polyps as in the normal nasal 
respiratory mucosa (Cauna et al. 1972). Histamine has been localised 
in the cytoplasm of mast cells by histofluorescent techniques 
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(Bumstead et al. 1979). High concentrations of free histamine have 
been found in fluid extracted from nasal polyps (Drake-Lee and 
McLaughan 1982). Mast cells have been shown to secrete histamine, 
heparin (Azizkhan et al. 1980, Marks et al. 1986) and tryptase (Blair et 
al. 1997), too. Stimulated mast cells and cognate cultured cell lines 
produce and secrete a variety of cytokines including tumour necrosis 
factor (TNF) (Baumgartner et al. 1994). The mast cell granules of 
polyps are relatively small and they either lack the outer lamellar 
element or are largely degranulated (Cauna et al. 1972). The bFGF is 
localised to the secretory granules in mast cells and may be released 
through degranulation (Qu et al. 1998). In a study by Drake-Lee et al. 
(1984a) polyp mast cells showed varying degrees of degranulation 
with vacuoles predominating examined by transmission electron 
microscopy. Electron-lucent and electron-dense material was found in 
some granules; crystalline structures and scrolls, normally seen in cells 
prior to degranulation, were found in otherwise degranulated vacuoles. 
These findings were thought to support the theory that mast cell 
degranulation in nasal polyps is in some way different from the more 
rapid changes found in cells activated by the classical IgE-mediated 
pathway. 
 
 
2.5.1.4.3. Other cells 
 
The polyp stroma regularly contains neutrophils, lymphocytes, 
monocytes, plasma cells and macrophages, in addition to eosinophils 
and mast cells (Cauna et al. 1972).  
 
 
2.6. TREATMENT OF NASAL POLYPS 
 
For most patients the management of nasal polyps comprises a 
combination of medical and surgical therapies. The recurrence of nasal 
polyposis constitutes a serious clinical problem. Recurrence rates up to 
29-53% have been reported (Blumstein and Tuft 1957, Jäntti-Alanko 
et al. 1985).  
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2.6.1. Medical treatment  
 
The recurrence of polyps may be slowed down by long-term topical 
corticosteroid treatment. Steroids have a multifactorial effect initiated 
by their binding to the cytoplasmic glucocorticoid receptor cell. The 
number of glucocorticoid receptors is reduced by glucocorticoid 
treatment (Knutson et al. 1996), but studies have not indicated any 
development of tachyphylaxis to therapy in nasal polyposis (Pedersen 
et al. 1976, Lildholdt et al. 1997) or in any other airway disease. 
Virolainen and Puhakka (1980) found a recurrence rate of 46% in a 
patient group treated with intranasal steroid (beclomethasone 
diprionate) while the corresponding figure was 87% in the placebo 
group at one year after ethmoidectomy. In a double-blind parallel-
group trial of budesonide versus placebo Holopainen et al. (1982) 
noted that the polyps diminished in number and size and total mean 
symptom scores and nasal peak flow values showed a statistically 
significant difference in favour of budenoside at the end of the four-
month trial period.  
 
Lildholdt et al. (1988) compared surgical removal of visible polyps 
with the efficacy of a single intramuscularly administered dose of 
betamethasone dipropionate and betamethasone disodium phosphate. 
In both groups, a nasal spray of beclomethasone dipropionate was 
used postinterventionally daily for one year. The results in terms of 
recurrences in the two treatment groups did not differ significantly. 
 
With regard to therapy most authors primarily prefer conservative 
medical therapy with steroids, but because of the side effects of 
systemic steroids and the strong recurrence tendency of polyposis 
surgery is often necessary in cases, which involve severe nasal 
obstruction or secondary infections (van Camp and Clement 1994).  
 
 
2.6.2. Surgical treatment  
 
Intranasal polypectomy may be performed under local or general 
anaesthesia and is traditionally performed using a snare, which may be 
cutting or avulsing.  
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The first description of an intranasal ethmoidectomy based on careful 
anatomical studies was credited to Mosher in 1913. He concluded that 
theoretically the operation was easy but in practise it had proven to be 
one of the easiest operations, which can kill the patient (Mosher 
1929). This was largely due to poor visualisation while entering the 
anterior cranial fossa during the surgery. Later, large series of patients 
mainly treated for polyposis in whom the overall complication rate 
was extremely low (Eichel 1972, Freedman and Kern 1979). 
 
In transantral ethmoidectomy the ethmoids are approached via the 
Caldwell-Luc procedure, but this method is very rarely recommended. 
The Caldwell-Luc operation is primarily designed for chronic 
maxillary sinusitis but it has been utilised for the removal of 
generalised polypoid disease, for fungal sinusitis and for the removal 
of antrochoanal polyps. 
 
Today removal of polyps and ethmoidectomy are done under 
endoscopic control. The anatomical knowledge derived from CT 
scanning has greatly enhanced precise removal of diseased tissue. If 
patients have recurrent sinusitis polypectomy and ethmoidectomy can 
be combined with uncinectomy and middle meatal antrostomy. The 
“shaver” is an ideal instrument to remove massive polyps. Mucosa and 
polyps are aspirated into a suction channel and cut by a blade 
oscillating in this channel.  
 
 
2.6.2.1. Complications of surgical treatment 
 
The most common complications of surgical treatment are bleeding 
and later postoperatively synechiae. Cerebrospinal fluid leak is a rare 
complication but patients with polyposis are at increased risk. 
Lacrimal and orbital injuries have also been reported (May et al. 
1994). Mucocele which can be caused by inflammatory obstruction of 
the sinus ostia can also be secondary to surgical manipulation 
(Jacobson et al. 1982, Alsarraf et al. 1999). 
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3. AIMS OF THE PRESENT STUDY 
 
 
In this study we wanted to find out the clinical course, outcome and 
diagnostic problems of nasal polyposis, and also to exam possible 
pathophysiologic and etiologic factors of two new research areas in 
nasal polyposis. 
 
The purposes of the study were: 
 
 
1. to elucidate the clinical course of nasal polyposis over a long period 
of time. 
2. to examine the reliability of A-US in detecting fluid retention or 
mucosal thickening in patients with chronic polypoid sinusitis 
using sinus CT as the decisive diagnostic test. 
3. to analyse the sense of smell in patients with long-standing nasal 
polyposis as compared to a healthy control material. 
4. to investigate the occurrence of VPF/VEGF in nasal polyps of 
patients with chronic nasal polyposis for two decades as compared 
to normal nasal mucosa.  
5. to find out the frequency of the two most common CF mutations in 
patients with chronic sinusitis with or without nasal polyps. 
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4. MATERIALS AND METHODS 
 
 
4.1. PATIENTS AND CONTROL SUBJECTS 
 
4.1.1. Patients  
 
Studies I-IV are based on a series of 109 patients who underwent 
polypectomy alone or in connection with ethmoidectomy at the 
Department of Otorhinolaryngology, University Central Hospital, 
Helsinki in 1977-78. The patients were then divided into three groups 
according to the results of clinical and allergological investigations 
(Holopainen et al. 1979):  
1. ASA intolerance = a definite history of ASA intolerance or a 
positive oral ASA provocation test (Juhlin et al. 1972). 
2. AT = a history of atopy or positive nasal provocation results 
concordant with positive skin test. 
3. INTR = diagnostic procedures for allergy revealed no specific 
etiologic factors. 
 
Of the initial series of 109 patients, 85 attended a follow-up 
examination four years after surgery (Jäntti-Alanko et al. 1985). Now 
at 20 years after surgery, we did a new follow-up examination. From 
those 85 patients in the first follow-up six patients had died, 19 
patients had moved away and two were not reached. Fifty-eight 
patients could be reached and were invited to the follow-up 
examination. Information on nasal symptoms, present and past history 
of nasal disorders, operations of the nose and paranasal sinuses, 
asthma-like symptoms, atopy, and ASA intolerance was gathered by a 
questionnaire sent to all subjects. Three of those 58 did not answer. 
Fourteen returned a completed questionnaire but did not come to the 
examination. Forty-one patients (26 men and 15 women, mean age 59 
years, range 35-84 years) attended this study in 1997. These 41 
patients were included in studies I and III. Study II consisted 40 of the 
41 patients (25 men and 15 women), because A-US was not available 
at the time of one patient’s control study. One maxillary sinus was 
”missing” because of a medial maxillectomy, leaving 79 sinuses for 
evaluation. Study IV included 39 of the 41 patients (24 were men and 
15 women), because biopsies were not obtained from two patients.  
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Study V is based on 127 chronic sinusitis patients, 35 men and 92 
female. The mean age was 44 years (range 7-83 years). The patients 
had been sent to the ENT (Ear, Nose and Throat) clinic because of 
chronic sinusitis. The criteria for chronic sinusitis were at least 8 
weeks of persistent sinusitis symptoms and signs, or four or more 
sinusitis episodes per year (Lund and Kennedy 1995). On average the 
chronic sinusitis symptoms had started 12 years earlier, but the range 
was large from 1 to 40 years. Thirty-four percent (43/127) of the 
patients had nasal polyposis and 31% (40/127) had asthma. Ninety-one 
percent (116/127) of the patients had had one or more operations for 
the maxillary sinus cavity; either inferior meatal antrostomy (57 
patients, 45%), endoscopic middle meatal sinus surgery with 
uncinectomia or middle meatal antrostomy (91 patients, 72%) and/or 
Caldwell-Luc (36 patients, 28%).  
 
 
4.1.2. Control subjects 
 
In study IV there were ten control patients who had no allergies 
anamnestically or nasal polyposis. The mean age of the control group 
was 44 years (range 17-77 years), 5 were men and 5 women. These 
control subjects underwent septoplasty (n=2), rhinoplasty (n=2), 
dacrocystorhinostomy (n=3), turbinoplasty (n=2) or decompression of 
the orbit (n=1) and during these operations a biopsy from the mucosa 
of the middle turbinate was taken with the permission of the patients. 
The diagnoses of these control patients were septal deviation (n=2), 
nasal deformation (n=2), dacryocystitis (n=3), hypertrophy of inferior 
turbinates and snoring (n=2) and endocrine exophthalmia (n=1). 
 
In study III the olfactory thresholds were compared with the earlier 
published results of a study in which the age-adjusted reference 
interval of the olfactory threshold was estimated with the same method 
(Simola and Malmberg 1998). The control group in the earlier study 
consisted of 104 subjects (56 women and 48 men, aged 17–71 years, 
mean 39 years) with no acute or chronic nasal complaints. 
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4.2. METHODS 
 
4.2.1. Long term follow-up study  
 
The patients were re-examined and classified now as were earlier into 
three groups (ASA, AT, INTR). All the patients were examined as 
follows: physical examination, sinus CT, A-US, olfactory threshold 
measurement, odour detection test, skin prick tests, nasal smears, 
active anterior rhinomanometer, acoustic rhinometer and a biopsy 
from a polyp or from the mucosa of the middle turbinate, if no polyp 
was seen. Information on nasal symptoms, present and past history of 
nasal disorders, subjective estimation of sense of smell, operations of 
the nose and paranasal sinuses, asthma-like symptoms, atopy, and 
ASA intolerance was gathered by means of a questionnaire completed 
by all subjects. 
 
 
4.2.1.1. Nasal polyposis in anterior rhinoscopy 
 
The status findings in anterior rhinoscopy were classified into four 
groups: 0 = no polyps, 1 = polypoid mucosa, 2 = small polyps, 3 = one 
big polyp, 4 = large polyposis. 
 
 
4.2.1.2. Imaging techniques  
 
A-US examination of the maxillary sinus and sinus CT were done in 
the course of 2 hours. All 79 sinuses were examined with A-US by an 
experienced ENT resident (investigator 1) and a second A-US 
examination was performed on 70 of the sinuses by a radiologist 
(investigator 2). The two investigators had no knowledge of the 
patient’s history, CT findings or the other investigator’s results. The 
US findings recorded by investigator 1 were carefully analysed for 
reliability by comparison with CT evidence. The results obtained by 
investigator 2 were primarily used to assess the reproducibility of A-
US diagnoses but they were also to find out the sensitivity and 
specificity of A-US in detecting fluid and mucosal thickening for two 
investigators. 
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4.2.1.2.1. A-US 
 
The A-US equipment used was a Sinus 320 (Entomed AB, Sweden) 
with a printer connection. The probe diameter was 13 mm and the 
transducer frequency 3.5 MHz. The probe was applied to the anterior 
wall of the maxillary sinus beneath the opening of infraorbital nerve, 
with the patient leaning his head a little forward so that the line from 
the external auditory meatus to the lower margin of the orbit was 
horizontal (Revonta 1980). The maximal echo was achieved with 
small movements of the probe. 
 
The A-US findings were classified into three groups: 1) almost normal 
mucosa = US echo received at a distance of < 1.5 cm; 2) thickened 
mucosa = US echo from a depth of more than 1.5 cm but less than 3.5 
cm; 3) total obliteration of the lumen or fluid level = US echo at a 
distance of  > 3.5 cm (= back wall echo). These criteria are modified 
from criteria by Revonta (1980). The results of US were compared to 
those of CT. 
 
 
4.2.1.2.2. Sinus CT 
 
CT scanning was done with a Somaton Plus 4 scanner (Siemens, 
Germany) and included coronal views to visualise all the paranasal 
sinuses and axial views of the maxillary sinus area. The coronal and 
axial images were done with a spiral technique (slice thickness 2 mm, 
a pitch of 2) and the images were reconstructed with a bone algorithm 
and viewed with a wide window (4000/900). The amount of fluid was 
estimated roughly in the coronal CT view by measuring the height of 
the sinus lumen and the height reached by the fluid level (expressed as 
percentage of sinus height ”volume”). The axial view of the maxillary 
sinus was also checked for the presence of fluid.  
 
The thickness of the mucosal swelling was measured in the axial view 
in the area directly below the infraorbital nerve. The thickness was 
classified into three groups: 1) normal mucosa or mucosal thickening 
< 0.5 cm, 2) mucosal thickening > 0.5 cm, 3) total obliteration of the 
air space or fluid level. 
 
Obliteration of the olfactory recesses was also evaluated from coronal 
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CT scans. The olfactory recesses are beneath the cribriform plates of 
the ethmoid bones, the superior turbinate being laterally and the nasal 
septum medially. They were recorded as open (totally/partly) or 
occluded (totally, both sides).  
 
 
4.2.1.3. Sense of smell 
 
The olfactory threshold was measured using a commercially available 
smell test kit (Olfacto-Labs, Berkeley, California). Olfactory detection 
thresholds were obtained using phenylethyl methyl ethyl carbinol sniff 
bottles. Subjects were asked to choose the bottle they thought 
contained the odorant, and the test was repeated three times at each 
step. The accepted olfactory threshold was the weakest concentration 
at which the subject picked the correct bottle all three times. The 
detailed method is described elsewhere (Amoore JE and Ollman BG 
1983, Amoore JE and O’ Neill RS 1986). The threshold was expressed 
in arbitrary logarithmic units (ALU), designated as ”decismels” (dS). 
The concentrations in use were —25, —15, —5, 5, 15, 25, 35, 45, and 
55 ALU. In the statistical analyses, the value of 65 ALU was used for 
those who could not identify the strongest concentration. The olfactory 
thresholds were compared with the earlier published results of a study, 
in which the age-adjusted reference interval of the olfactory threshold 
was estimated with the same method (Simola and Malmberg 1998). In 
brief, the age-related 95% reference interval was calculated by first 
fitting a linear regression model to the olfactory threshold data. 
Another linear regression model was fitted to the standard deviations 
of the residuals about the first regression. The reference interval was 
calculated as 
f1(age) ± 1.96 × f2(age) 
where f1 and f2 are the functions of age fitted to the threshold data and 
the residuals, respectively. The threshold was considered as hyposmia, 
if it exceeded the upper age-related reference limit and 65 ALU as 
anosmia (Simola and Malmberg 1998) in study III. In study I the 
olfactory thresholds were compared with the reference values given by 
the manufacturer (—25 to 25 = normal sense of smell, 35 to 55 = 
hyposmia and over 55 ALU = anosmia). 
 
The sense of smell of polyposis patients was also assessed using a 
detection test with 7 different odours. The odours used were coffee, 
cinnamon, spirit, vanillin, camphor, turpentine and gasoline. In this 
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test, detection also without identification of the odour was accepted. 
The patients were categorised into three groups; 1) patient detected all 
7 odours, 2) patient detected 4 to 6 odours, 3) patient detected less 
than 4 odours.  
 
 
4.2.1.4. Rhinomanometry and acoustic rhinometry 
 
NR6-2 computerised active anterior rhinomanometer (G.M. 
Instruments Ltd., Glasgow, UK) was used to measure the nasal 
resistance of polyposis patients. The nasal resistance was measured on 
each side of a Broms 200 units circle and the total nasal resistance was 
calculated. The volume between the distances of 4 to 7 cm from the 
nostrils was measured with an A1/2 Acoustic Rhinometer (G.M. 
Instruments Ltd., Glasgow, UK). The sum of unilateral volumes was 
calculated for all patients. The nasal mucosa was decongested by 
inhalation of 0.5% xylometazoline hydrochloride nasal spray in each 
nasal cavity 15 minutes before the measurements. The values of nasal 
resistance and nasal volume were logarithmically transformed to 
achieve a fairly normal distribution, and these values were used in 
statistical analysis. 
 
 
4.2.1.5. Allergy tests 
 
Skin prick tests to 22 common environmental allergens (Soluprick® 
allergen solutions, ALK, Denmark) were performed on all patients. 
The patient was considered prick-test positive (atopic), if at least one 
allergen elicited a weal whose diameter was at least 3 mm larger than 
that of the negative control. 
 
 
4.2.1.6. Nasal smears 
 
The secretion eosinophils were scored as negative or positive 
according to a semiquantitative microscopic evaluation (Hansel 1951).  
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4.2.1.7. Biopsies 
 
A biopsy was taken from a polyp or from the mucosa of the middle 
turbinate, if no polyp was seen. In control subjects the biopsy was 
taken from mucosa of the middle turbinate. The biopsy specimens 
were frozen in liquid nitrogen, sectioned and stained with hematoxylin 
and eosin for detection of structural components and inflammatory 
cells. The biopsy specimen was considered to show tissue eosinophilia 
if there were 20 or more eosinophils per 100 inflammatory cells 
(Holopainen et al. 1979). 
 
 
4.2.1.8. Determination of VPF/VEGF expression 
 
VPF/VEGF expression was determined using a mouse monoclonal 
antihuman VPF/VEGF antibody (MAB293, IgG2b class, R&D 
Research, MN, USA) raised against the 165 amino acid form of the 
polypeptide. The 5-µm frozen sections were rehydrated, incubated for 
30 min in 0.3% hydrogen peroxidase in methanol at room temperature, 
and for 20 min in 5% normal horse serum at room temperature. The 
sections were incubated overnight at 4 °C with the primary antibody at 
a dilution of 1:24. A subsequent incubation for 30 min in biotinylated 
anti-mouse serum was followed by a 30 min incubation using reagents 
of the vectastain Elite ABC kit (Vector laboratories, Burlingame, CA, 
USA). Peroxidase activity was developed with 3-amino-9-ethyl 
carbazole (Sigma, St Louis MO, USA) for 10 min. Finally, the 
sections were stained with haematoxylin for 5 min. A pathologist 
(CHJW) who was blinded to the patient data examined all the 
samples. 
 
The percentage of the surface epithelium that stained for VPF/VEGF 
was estimated and the intensity of staining was graded from 1 to 5. 
The percentage of the VPF/VEGF stained epithelium of nasal glands 
was also estimated, and the intensity was similarly graded. The 
amount of VPF/VEGF (x (unit) = a(%)*b/c(%)) was calculated using 
the equation: x = a (percentage of relevant epithelium) that stained for 
VPF/VEGF) * b (the intensity of staining) / c (percentage of relevant 
epithelium of all epithelium). 
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4.2.2. Determination of cystic fibrosis gene mutation carriers 
(394delTT and F508) in patients with chronic sinusitis 
 
Genomic DNA was isolated from the whole blood specimens 
according to standard protocols. Positive controls from CF patients 
were used (Kere et al. 1994). The primers used were  
5’-CTGGAGCCTTCAGAGGGTAAAAT-3’ and  
5’-CATGCTTTGATGACGCTTCTGTA-3’ for F508, and  
5’-CTTGGGTTAATCTCCTTGGA-3’ and  
5’-ATTCACCAGATTTCGTAGTC-3’ for 394delTT.  
 
Each reaction contained 10 µl 5 ng/µl DNA, 2 µl 2mM dNTP, 0.12 µl 
5 U Taq polymerase (AB Applied Biosystems), Gold buffer 
polymerase (AB Applied Biosystems), 0.5 µl 20 µM of each primer, 
0.2 µl DMSO4 and 4.7 µl H20. The reaction mixture was submitted to 
amplification for 30 cycles. The temperatures and times for 394delTT 
were denaturation 30 s at 95 ºC, annealing 40 s at 53 ºC and extension 
40 s at 72 ºC. The temperatures for F508 were 1.5 min at 95 ºC, 1.5 
min at 65 ºC and 1.5 min at 72 ºC, respectively. HinfI digestion was 
performed for polymerase chain reaction (PCR) products to detect 
394delTT mutations. The sizes of the amplified fragments were: 1) 
F508: for normals 148 and for carriers 145, and 2) 394delTT: after 
HinfI digestion for normals 32 + 172 + 105 and for carriers 32 + 172 + 
103 (GenBank AH006034). The PCR products were then 
electrophoresed on 6% polyacrylamide gels, silver stained and 
scanned. 
 
 
4.2.3. Statistical analysis 
 
The statistical significances between the ASA, AT and INTR groups 
in the occurrence of asthma and in the use of nasal steroids were tested 
by the Chi squared test and the degree of obliteration of sinuses in CT 
and the amount of reoperations were tested by the Kruskal–Wallis 
one-way analysis of variance (ANOVA) test (I). 
 
To examine the sense of smell in polyposis patients, we compared 
their olfactory thresholds with the thresholds in the group of the 
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reference subjects (Simola and Malmberg 1998). Stepwise multiple 
linear regression analysis (STATISTICA for Windows, StatSoft, Inc., 
Tulsa, OK) was used to examine the associations between olfactory 
threshold and age, gender, polyposis in anterior rhinoscopy (0 = no 
polyps, 1 = polypoid mucosa, 2 = small polyps, 3 = one big polyp, 4 = 
large polyposis), nasal resistance, nasal volume, the degree of opacity 
of the ethmoidal sinuses, ASA intolerance, allergy, diagnosed asthma, 
and the number of polypectomies or ethmoidal operations in the 
patient group. The Kappa statistic was used to assess the agreement 
levels between the olfactory threshold and odour detection tests and 
between the subjective estimation of the sense of smell and the 
measurement of olfactory threshold and odour detection test. 
According to Altman (1994), kappa values of 0.20 or less reflect poor 
agreement, with values of 0.21–0.40, 0.41–0.60, 0.61–0.80 and 0.81–
1.00 the strength of agreement is fair, moderate, good or very good, 
respectively. For these purposes, the ranges of the measurements were 
divided into three groups (olfactory threshold: —25 to 25, 35 to 55 
and over 55 ALU; odour detection test: 7, 3 to 6 and less than 3 
correct detections; subjective estimation: normal, impaired, loss of 
sense of smell). Comparison of groups was made with ANOVA and 
the Chi squared test. Spearman's rank order coefficients were 
calculated for the association between odour detection and olfactory 
threshold test of the sense of smell (III).  
 
The statistical significances between the amount of VPF/VEGF and 
ASA intolerance, AT and IT groups were tested using the Kruskal–
Wallis one-way ANOVA test. The Mann–Whitney U-test was used in 
comparisons of the amount of VPF/VEGF between the polyposis 
patients and the control patients. The Spearman correlation coefficient 
was used in comparisons of the amount of VPF/VEGF to the number 
of polyp operations, the degree of mucosal obliteration of ethmoidal 
sinuses in CT, the number of eosinophils, mast cells and the status 
findings (IV).  

RESULTS  
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Fourteen of 58 patients sent a questionnaire completed by themselves 
but did not come to the examination. In this questionnaire 6 patients 
stated their polyp disease had resolved, 5 stated the activity of the 
polyp disease had diminished, one stated it was the same as twenty 
years ago and 2 stated that nasal polyposis had worsened. Altogether 
71% (39/55) of the patients who completed questionnaires thought 
that their polyp disease had resolved or the activity of the polyp 
disease had diminished (unpublished result). 
 
Bronchial asthma had been diagnosed in 44% (18/41) of the patients. 
Bronchial asthma was found in 100% (11/11) in the ASA intolerance 
group, in 36% (4/11) in the AT and in 16% (3/19) in the INTR group.  
 
 
5.1.2. Operations during the follow-up period and present medical 
treatment (I) 
 
Thirty-seven patients (90%) had had a re-operation during the 
previous 20 years. In those four non-operated patients rhinoscopy 
revealed many large polyps in two patients, polypoid mucosa in one 
patient and normal mucosa in one patient. Eight patients (20%) had 
had 11 or more nasal re-operations (re-polypectomy or anterior 
ethmoidectomy by endonasal approach), 7 (88%) of them belonging to 
the ASA intolerance group (Fig. 2). There was statistical significance 
in the amount of nasal re-operations in the ASA patients compared 
with AT and INTR patients (P < 0.0001). The Caldwell-Luc operation 
had been performed on 41% (17/41) of the patients, on both sides in 
14 cases. Five patients had undergone the Caldwell-Luc operation 
before the initial study in 1977-8 but 2 of them had had re-Caldwell-
Luc operations during the previous 20 years. Medial maxillectomy had 
been performed on one patient because of an inverted papilloma. 
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5.1.4. A-mode ultrasound in the diagnosis of fluid retention or 
mucosal thickening in patients with chronic polypoid sinusitis (II) 
 
Twenty of seventy-nine (25%) maxillary sinuses showed fluid levels 
or complete obliteration on the CT scans. Only 30% (6/20) of these 
abnormalities were detected with A-US. Fourteen fluid-containing or 
totally obliterated maxillary sinuses were not detected with A-US. 
According to the CT, fluid filled less than 30% of the lumen in 5 of 
these sinuses and in two an echo suggesting mucosal thickening was 
obtained. A-US findings were false positive in 14% (11/79) (Table I). 
In 6 cases, a back wall echo was received probably through a polypoid 
mass, although according to the CT, the maxillary sinus was not 
totally obliterated. For investigator 1, the sensitivity of A-US in 
detecting fluid or total obliteration was 30% and the specificity 81% 
and for investigator 2 28% and 69%, respectively.  
 
The thickness of the mucosa was estimated in the 59 sinuses, which 
were not fluid-containing or completely obliterated. There was 
mucosal thickening in 30 (51%) maxillary sinuses according to CT. 
Twelve of these 30 (40%) were detected with A-US. For 15 sinuses 
(25%) A-US findings were false positive (Table II). In detecting 
mucosal thickening the sensitivity of A-US was 40% and the 
specificity 48% for investigator 1 and 50% and 58%, respectively, for 
investigator 2.  
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The anterior wall of the maxillary sinus had been operated on in 30 
cases. In these sinuses the sensitivity of A-US was 17% and the 
specificity 86% in detecting fluid or total obliteration, and 64% and 
40% respectively, in detecting the mucosal swelling. 
 
In the non-operated maxillary sinuses (n=49) the sensitivity of A-US 
was 36% and the specificity 77% in detecting fluid or total 
obliteration, and 19% and 53% in detecting the mucosal swelling. 
The two investigators obtained identical A-US results in only 35 of 70 
sinuses (50%).  
 
 
5.1.5. Sense of smell (III) 
 
5.1.5.1. Subjective estimation 
 
Ten of 41 (24.4%) patients thought they had anosmia, 23/41 (56.1%) 
patients thought they had hyposmia and 8/41 (19.5%) thought they had 
a normal sense of smell.  
 
 
5.1.5.2. The olfactory threshold  
 
The average olfactory threshold was 39.9 ALU (SD 25.0) in the 
patient group and 13.8 ALU (SD 11.2) in the reference group. In 19 
(46%) of 41 patients the threshold was greater than the age-related 
upper limit of the 95% reference interval (anosmia n=16, hyposmia 
n=3) (III). As compared with the 1.9% rate (2/104) in the reference 
subjects, the percentage was significantly higher (difference between 
the proportions 0.44, 95% confidence interval 0.29–0.60, χ² = 46.85, P 
< 0.001). In the forward stepwise multiple linear regression analysis of 
all patients, the degree of obliteration of ethmoidal sinuses in CT (P = 
0.008), polyposis seen in anterior rhinoscopy (P = 0.023), the 
logarithmically transformed total nasal resistance (P = 0.01) and 
gender (P = 0.048) (men had a better sense of smell than women) 
showed significant association with olfactory thresholds. The 
association of atopy and olfactory threshold was not significant (P = 
0.31). In the ANOVA with degree of obliteration of ethmoidal sinuses 
and the logarithmically transformed total nasal resistance as 
covariates, the difference between men’s and women’s olfactory 
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thresholds was not significant (F1,34 = 2.60, P = 0.12), the adjusted 
means being 36.8 ALU and 47.6 ALU, respectively. In the group of 29 
patients with their olfactory recesses at least partially unobstructed, 5 
(17%) had anosmia, 2 (7%) hyposmia and 22 (76%) normal olfactory 
thresholds, whereas, the corresponding figures were 11 (92%), 1 (8%) 
and 0 in the group with total obliteration of both olfactory recesses (χ² 
= 21.17, P < 0.0001) (unpublished result). In the ANOVA with age as 
a covariate, the difference between the patients with total obliteration 
of both olfactory recesses and the patients with at least partly open 
olfactory recesses was significant (F1.38 = 26.71, P < 0.0001), the 
adjusted means being 64.2 and 29.3 ALU (unpublished result). 
 
When the olfactory thresholds were compared with the reference 
olfactory threshold values given by the manufacturer anosmia or 
hyposmia was found in 61% (25/41) of the patients (I). 
 
 
5.1.5.3. The smell identification test  
 
Twelve of 41 patients detected less than 4 odours, 6 patients detected 
from 4 to 6 odours and 23 patients detected all 7 odours. 
 
In the assessment of the agreement between the odour detection 
olfactory threshold and smell identification test, the value of kappa 
was calculated as 0.51 (95% confidence interval 0.28–0.73).  
 
The Spearman rank order correlation coefficients between the 
subjective estimation of the sense of smell and the measurement of 
olfactory threshold and smell identification test were 0.62 (P < 
0.0001) and 0.60 (P < 0.0001), respectively. The corresponding kappa 
values as measures of agreement were 0.38 (95% confidence interval 
0.17–0.60) and 0.37 (0.16–0.58). 
 
 
5.1.6. Allergy tests (I) 
 
Fourteen patients had positive skin reactions to the allergen panel 
used. Eleven of them formed the AT group and 3 had also ASA 
intolerance and were taken into the ASA group.  
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5.1.6.1. Changes in the three groups (ASA intolerance, AT, 
INTR)  
 
Eleven patients out of 41 belonged to the ASA intolerance group, 19 
patients to the INTR group and 11 patients to the AT group. During 20 
years the following changes had occurred: one ASA intolerant patient 
and 6 INTR patients were now skin prick test positive, and one of 
these INTR patients had also become ASA intolerant. Another INTR 
patient had become ASA intolerant, too. One ASA intolerant patient 
whose earlier skin tests had been positive and two patients classified 
as atopics were now negative on skin testing. 
 
 
5.1.7. Tissue and secretion eosinophilia (I) 
 
Biopsies were available from 40 patients and smears from all these 
patients. Tissue eosinophilia was found in 63% of the patients but 
secretion eosinophilia in only 25%. Six biopsies were from the 
mucosa of the middle turbinate and tissue eosinophilia was found in 
four of them. Twenty years earlier tissue eosinophils were positive in 
94% and secretion eosinophils in 89%, respectively in 109 patients 
(Holopainen et al. 1979) 
 
 
5.1.8. Vascular permeability factor/vascular endothelial growth 
factor in nasal polyps (IV) 
 
VPF/VEGF was found on the surface epithelial cells of the mucosa, 
and in the nasal glands in both polyposis and control patients. 
VPF/VEGF was mostly found in the surface epithelium containing 
goblet cells. There was more VPF/VEGF in the surface epithelium in 
control patients than in polyposis patients, but it was not statistically 
significant (P = 0.0525). There were sections without any 
immunoreactivity for VPF/VEGF in the surface epithelium in 19/39 
polyposis patients and in 2/10 control patients. The epithelium of nasal 
glands was found in 25/39 samples from polyposis patients and in 5 of 
these samples there was no immunoreactivity for VPF/VEGF, while 
immunoreactivity for VPF/VEGF was seen in the nasal glands of 
every control patient. There was more VPF/VEGF expression in the 
epithelium of nasal glands in control patients than in polyposis 
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patients (P < 0.002). VPF/VEGF immunoreactivity was also seen in 
stromal non-degranulated mast cells from two polyposis patients, 
however capillaries were not found in these biopsies. Almost all mast 
cells in the other samples both controls’ and patients’ were 
degranulated and in these cases there was no clear staining for 
VPF/VEGF.  
 
There were no statistical significances between the amount of 
VPF/VEGF and asthma, ASA intolerance, AT or IT groups (the 
Kruskal–Wallis one-way ANOVA-test). The amount of VPF/VEGF 
correlated poorly to the number of polyp operations (Spearman index 
0.19 in the surface epithelium and -0.19 in the epithelium of nasal 
glands). The correlation was also poor (0.32 and -0.07) when the 
amount of VPF/VEGF was compared to the degree of mucosal 
obliteration of ethmoidal sinuses in CT. There were no correlations 
either with the number of eosinophils, mast cells or with the status 
findings.  
 
 
5.2. THE FREQUENCY OF CF MUTATIONS IN PATIENTS 
WITH CHRONIC SINUSITIS (V) 
 
For this analysis there were DNA specimens from 127 patients. We 
found one carrier of the 394delTT mutation. This patient had no nasal 
polyps and her immunoglobulin levels were normal. However, her 
grandparents come from an area where the mutation 394delTT is 
enriched (Kere et al. 1994). None of the DNA specimens had a F508 
mutation.  
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6. DISCUSSION 
 
 
This study covers a period of 20 years of a chronic and probably life-
lasting disease. The basic series consisted of 109 patients with nasal 
polyposis diagnosed in a clinical examination and the polyps were 
removed for microscopic examinations in polypectomy or 
ethmoidectomy operations in 1977-78 at the Department of 
Otorhinolaryngology, University Central Hospital, Helsinki. From the 
85 patients in the first follow-up (Jäntti-Alanko et al. 1985) six 
patients had died, 19 patients had moved away from our area and two 
were not reached. Fifty-eight patients could be reached and were 
invited to the follow-up examination but 17 patients did not come. It is 
possible that the 41 who came could represent patients with the most 
troublesome symptoms. But 68% (28/41) of those who came and 79% 
(11/14) of those who only returned the completed questionnaire but 
did not come to the examination thought that their polyp disease had 
been resolved or the activity of the polyp disease had diminished and 
only 10% (4/41) and 14% (2/14) that their nasal polyposis had 
worsened and in that respect the patients in both groups were very 
much alike. Death or moving house are ”accepted reasons” not to 
come and so the selection was maybe not very markedly affected and 
this follow-up material could be rather representative of the original 
sample.  
 
The patients were classified both in the earlier study in 1977-78 
(Holopainen et al. 1979) and in this follow-up study 20 years later 
using rather similar criteria based on an allergy examination into three 
groups: ASA, AT and INTR. In our study INTR patients would have 
largely represented NARES patients but according to Monoret-Vautrin 
et al. (1990) this syndrome is a precursor of the Samter’s triad and in 
our study INTR patients had not become ASA intolerant with 2 
exceptions over 20 years. The etiology of nasal polyposis is not known 
but the allergological division we used somehow subdivides the 
groups.  
 
Besides the ”classical” allergologic criteria some more recent 
techniques were used in this analysis such as rhinomanometry, 
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acoustic rhinometry, olfactory threshold measurements, sinus CT and 
A-US.  
 
Growth factors in nasal polyposis have been a subject of discussion in 
recent times. Of those the VEGF-family seemed theoretically 
interesting and it was much studied in our collaborators’ laboratory. 
This was the reason we studied the occurrence of VEGF in nasal 
polyposis. Nasal polyps are found in 20-48% of CF adult patients (di 
Sant’ Agnese and Davis 1979, Aitken and Fiel 1993). This is a 
hereditary disease caused by an autosomal-recessive defect of the 
CFTR gene on chromosome 7 (Kerem et al. 1989, Riordan et al. 1989, 
Rommens et al. 1989). There are some suspicions that the prevalence 
of carriers of CF gene in nasal polyposis and/or chronic sinusitis 
patients could be higher than in the population on average (Irving et al. 
1997, Wang et al. 1998). Although this disease is very rare in Finland 
the possibility of overrepresentation of CF gene carriers in chronic 
sinusitis patients with or without polyps was studied in an independent 
study.  
 
 
6.1 NASAL POLYPOSIS - CLINICAL COURSE DURING 20 
YEARS (I) 
 
Long-term follow-up studies of nasal polyps have earlier been reported 
by Blumstein and Tuft (1957), by Larsen and Tos (1994, 1997), and by 
Jäntti-Alanko et al. (1985) from this same material in our Department. 
The study published by Blumstein and Tuft (1957) consisted 77 
patients with recurrent nasal polyps. This study claimed to show that 
allergy treatment prevented further recurrences in 47% of patients 
followed for 4.3 years. An additional 22% followed for 5 years 
partially benefited from treatment, as judged by the lengthened 
interval between polypectomies. Thirty-one percent of the patients 
followed from 5 to 7 years failed to respond to allergy treatment, either 
alone or combined with other forms of therapy. In this group there 
were many intractable asthmatics and poorest results were obtained in 
a group labelled ”nonsensitive”, those with negative skin reactions and 
no determinable specific etiology. This follow-up showed that patients 
with the highest recurrence of nasal polyps were ”nonsensitive” with a 
high incidence of asthma while patients with identifiable and 
controllable allergies had the lowest recurrence of polyps. In the 
present study AT patients seemed also to have a better prognosis, than 
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ASA and INTR patients although only 45% of AT patients used 
topical steroids.  
 
Larsen and Tos described the clinical course of primary nasal 
polyposis in 180 patients in 1994, the follow-up time being 1 to 8 
years (median 57 months). Ninety-six patients belonged to one or 
more of the etiopathogenetic subgroups of asthma, acute recurrent or 
chronic sinusitis, ASA intolerance or allergy. Sixty-six percent 
(118/180) did not undergo further polypectomies during the 
observation time (median 52 months) but they found that patients with 
asthma, acute recurrent or chronic sinusitis, ASA intolerance or 
allergy (39 of 62 patients belonged to one or more subgroups 
mentioned above) required more polypectomies and more topical 
steroid treatment than patients without these conditions. No significant 
difference in the number of polypectomies was observed between 
patients with asthma, sinusitis and allergy. The individual patient 
could be represented in one or more of the aetiopathogenic subgroups 
that were compared which was not the case in our study and so we can 
not compare these results unambiguously with the present study. The 
small number of patients with ASA intolerance did not allow 
statistical analysis in the study of Larsen and Tos (1994).  
 
Larsen and Tos have also described another study of nasal polyp 
patients followed for approximately 8 years (38-145 months) after 
simple polypectomies. They found that ASA intolerant patients had 
the highest number of polypectomies, patients with asthma had more 
polypectomies than those without and the subjective estimation of 
olfaction representing anosmia or hyposmia was 45% of the patients. 
These results are very much like ours’ except that in our study 80% of 
the subjects thought they had anosmia or hyposmia. 
 
To the best of our knowledge studies with a follow-up time as long as 
20 years with this group size (n=41) have not been published before. 
 
It is a common clinical opinion that the recurrence and activity of 
nasal polyposis diminishes with time. Thus, it was surprising that 
nasal polyps were still affecting most of our patients. Nasal polyposis 
was seen in 85% of patients in anterior rhinoscopy. This percentage 
may be too low, because nasoendoscopy would probably have given 
even higher figures for polyposis (Penttilä et al. 1990). Also 68% of 
these 41 patients thought that their polyp disease was less disturbing or 
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had even disappeared over the 20 years, which then was not found to 
be the case. This means that the patients can not identify their polyp 
disease and they should be followed for years because relieving 
treatment can then be offered.  
 
The prevalence of asthma (44%) in this study population was 
considerably higher than in population on average (Sears 1997). The 
differences in asthma prevalence were clear among these three groups 
but the groups were too small for analysis of statistical significance. 
The method used to collect data for the prevalence of asthma was 
anamnestic and the data was obtained using the questionnaire.  
 
In most cases (16/18) bronchial asthma had been diagnosed before 
nasal polyposis but the first follow-up study (Jäntti-Alanko et al. 1985) 
already showed that bronchial asthma was diagnosed after nasal 
polyposis in 4 patients and now in this study 2 more patients had 
developed asthma after the first follow-up examination. The clinical 
relationship of nasal polyps to asthma has been analysed in many 
studies. It has been found that polyps developed earlier than asthma in 
22% (Granström et al. 1992) to 33% of individuals (Schenk 1974) and 
the mean interval from onset of polyps to the development of asthma 
varied between 2 and 12 years (Schenk 1974). In  Blumstein and Tuft’s 
study (1957) they noted that patients belonging to the recurrent group 
are more likely to develop their asthma after polyps had been detected 
and repeatedly removed. There are also studies in which asthma 
developed first at a mean of 67% to 73% of the patients and the mean 
interval from onset of asthma to the development of polyps varied 
between 7 and 13 years (Schenk 1974, Larsen and Tos 1994) 
 
It is probable that many patients had adjusted themselves to their 
polyp disease and its symptoms; nasal blockage, rhinorrhea, sneezing, 
sinusitis and hyposmia. Although 68% (28/41) of the patients thought 
that their polyp disease was less disturbing or had even disappeared 
during the 20 years anterior rhinoscopy showed that 85% of these 
patients still had nasal polyposis. Some patients (11/41) with massive 
polyposis in the anterior rhinoscopy or sinus CT were operated on and 
afterwards experienced considerable relief for at least nasal stuffiness. 
 
There had been little intergroup change between ASA intolerance, AT 
and INTR groups over 20 years. One ASA intolerant patient and 6 
INTR patients were now skin prick test positive and one ASA 
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intolerant patient for whom earlier skin tests had been positive and 
two patients classified earlier as atopics were now negative on skin 
testing. The new positive reactions can be considered as real positives, 
because skin reactivity decreases with increasing age (Simola et al. 
1999). This decrease of skin reactivity may also explain why two 
patients classified as atopics were now negative on skin testing.  
 
Tissue eosinophilia was found in 63% of the polyps but secretion 
eosinophilia in only 25%. Twenty years earlier tissue eosinophils in 
polyps were positive in 94% and secretion eosinophils in 89% of 109 
patients (Holopainen et al. 1979). Both secretion eosinophilia and 
tissue eosinophilia were found most often in ASA patients who also 
had the most active nasal polyposis as judged by the degree of sinus 
involvement and number of re-operations and use of medication (91% 
used topical corticosteroids). Tissue eosinophilia seems to be an 
indicator of the active disease process in the nasal polyposis. 
 
The patients with ASA intolerance had a higher recurrence frequency 
and a greater need for surgical treatment than the patients in the AT 
and INTR groups and in that respect they have a poor prognosis. This 
indicates that ASA intolerance is an important prognostic factor for 
the clinical course of nasal polyposis. AT patients seemed to have a 
better prognosis: they had fewer recurrences, milder mucosal 
pathology and they needed or used less intranasal steroids than 
patients in the ASA and INTR groups. Allergy is probably not a 
causative factor in nasal polyposis.  
 
We need to know more about the pathophysiology of nasal polyposis 
to be able to develop more effective treatments and to identify more 
factors relevant to the prognosis of the disease. 
 
 
6.2. A-MODE ULTRASOUND IN THE DIAGNOSIS OF 
FLUID RETENTION IN PATIENTS WITH CHRONIC 
POLYPOID SINUSITIS (II) 
 
Some earlier studies on the reliability of A-US in diagnosing sinusitis 
with fluid retention have produced rather contradictory results. This 
may partly depend on the patient material, which may have been very 
heterogeneous including both pure simple acute sinusitis patients and 
possibly more chronic or even operated cases. In this study, we 
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The rather large diameter (13 mm) of the probe may also have affected 
the results. A narrower probe could possibly be placed more accurately 
in position on these deformed anterior walls. The probe is narrower (8 
mm, Sinuscan 102®, Finland) in the latest models of the A-US 
equipment.  
 
Of course, the examination technique in use of A-US may also be 
questioned. We made the measurements in a rather small area 
corresponding to the area below the anticipated opening of the 
infraorbital nerve. Therefore, very small amounts of fluid were 
probably missed. But if an echo is received from a depth of less than 
3.5 cm in the lower parts of the sinus, it is impossible to determine 
whether there is only mucosal thickening or a back wall echo from the 
smaller inferior recess of the antrum. A positive A-US finding 
suggesting the presence of fluid is regarded as an indication for sinus 
lavage. If such echoes are accepted as signs of fluid retention, many of 
the lavages will probable be negative. Then the benefit of using A-US 
is actually lost. The results of our study lead us not to recommend A-
US to diagnose fluid retention or mucosal swelling in patients with 
chronic mucosal changes in their maxillary sinuses or if surgery has 
been performed on the anterior wall of the maxillary sinus. 
 
 
6.3. SENSE OF SMELL IN CHRONIC NASAL POLYPOSIS (III) 
 
According to our results, long-standing nasal polyposis was clearly 
related to an impaired sense of smell. In 19 (46%) of 41 patients the 
threshold was greater than the age-related upper limit of the 95% 
reference interval. As compared with the 1.9% rate (2/104) in the 
group of the reference subjects and with the 15% rate (16/105) in 
chronic rhinitis patients (Simola and Malmberg 1998), the percentage 
was very high. In a previous study of a group of chronic sinusitis 
patients (n=115) before functional endoscopic surgery, anosmia was 
found in 31% and hyposmia in 52% of the group (Delank and Stoll 
1998). 
 
Our patients had a greater residual olfaction in the odour detection test 
than in the olfactory threshold test for their sense of smell, but even 
though the patients in the first mentioned test could detect the odours, 
they could not identify them. This could be a sign of normal olfaction, 
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but also may be due to some kind of dysosmia or defective olfactory 
function (Douek et al. 1975). 
 
In the assessment of the agreement between the olfactory threshold 
and the odour detection test, the value of kappa was calculated as 0.51 
(95% confidence interval 0.28–0.73) and according to Altman (1994) 
in our data there seemed to be a moderate consistency between the 
simpler odour detection test and the more modern olfactory threshold. 
 
Although anosmia or hyposmia were common, it seemed not to 
disturb the patients. One explanation might be that as most polyp 
tissue was found in the paranasal sinuses there were not so many 
polyps in the nasal cavities. Thus the patients may have felt symptom 
free because breathing via the nasal cavities was possible and they had 
grown accustomed to anosmia and head pressure over the years. 
 
Total obliteration of both olfactory recesses and the degree of 
obliteration of the ethmoidal sinuses compared with olfactory 
threshold showed a significant correlation in our study. This is 
probably a typical conductive anosmia, where polyp masses obturate 
the upper airway passage. This is supported by the findings that 
postoperative steroid treatment or steroid treatment alone may 
improve the sense of smell by decongesting the mucosa (Jafek et al. 
1987, Scott 1988). Many studies report the recovery of olfaction due 
to effective anti-inflammatory therapy (systemic or local steroids), 
surgical therapy or a combination of both, implicating conductive 
etiology (Jafek et al. 1987, Mott et al. 1997). Jafek et al. (1987) 
reported two anosmia patients with long-term reversal of the anosmia 
utilising a combination of surgical and pharmacological intervention. 
It would probably be optimal to combine surgery with steroid 
treatment every time to achieve permanent better results of olfactory 
function. But also irreversible impairment of the sense of smell has 
been found.  
 
There were 5 patients who had anosmia although their olfactory 
recesses were open and one of these 5 patients had only slight 
obliteration in her ethmoidal sinuses in CT. This could be due to 
inflammatory degenerative changes of the nasal attic or ethmoidal 
mucosa, but also due to many polyp operations with scarring or also 
degenerative changes of the olfactory mucosa due to the chronic polyp 
disease and recurrent infections or their treatment causing sensory 
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olfactory destruction.  
 
According to Simola and Malmberg (1998) a history of recurrent 
polyp operations was associated with poorer smell test results in a 
group of chronic rhinosinusitis patients. But only some of them had 
nasal polyps, so this group was more heterogeneous than ours. 
Hosemann et al. (1993) found that 87% of those patients in whom 
ethmoidal surgery did not improve the hyposmia or anosmia had 
already had earlier surgical interventions on their paranasal sinuses. 
However, in our study there was no significant association between 
olfactory threshold and the number of polypectomies or ethmoidal 
operations, this may be because all patients in our study had polyp 
disease but this was not true for all the patients in the study mentioned 
above.  
 
Atopy and olfactory threshold did not show significant association (P 
= 0.31). In a study of Simola and Malmberg (1998) prick-test 
positivity was associated with better smell-test results in long-
continuing rhinitis group. This may also be explained by the fact that 
all patients had polyp disease in our study this was not true for all the 
patients in the study mentioned above.  
 
There was an inverse association between olfactory threshold and the 
logarithmically transformed total nasal resistance. Maybe there were 
some patients who had hyposmia not caused by nasal obstruction but 
instead by degenerative changes in the olfactory mucosa which caused 
sensoneural defect. For example in the present study there were two 
patients who had anosmia, but very good flow in rhinomanometry.  
 
The male gender was associated with a better olfactory threshold in 
the regression analysis, but in the ANOVA with degree of obliteration 
of ethmoidal sinuses and the logarithmically transformed total nasal 
resistance as covariates, the difference between male and female 
olfactory thresholds was not significant (P = 0.12). There was no 
gender-association with the smell-test results for the group of the 
reference subjects (Simola and Malmberg 1998). Metabolic changes 
may affect the sense of smell, and in women e.g. hormonal changes 
may induce hypertrophic and hyperaemic effects in the respiratory 
mucosa of the nose as Douek (1975) has also speculated. 
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The method for smell identification and the kit used in this study for 
measuring olfactory threshold do not distinguish between a 
sensorineural and a conductive defect. A biopsy from the olfactory 
mucosa of the patients would have given further information about 
possible degenerative mucosal changes, which have been discovered 
in the olfactory mucosa of the patient with anosmia followed by 
influenza (Douek et al. 1975). 
 
 
6.4. VASCULAR PERMEABILITY FACTOR/VASCULAR 
ENDOTHELIAL GROWTH FACTOR IN NASAL POLYPS (IV)  
 
There are fewer blood vessels and they are of smaller diameter in nasal 
polyps than in healthy nasal mucosa (Cauna et al. 1972), but the 
permeability of capillaries and small vessels is high both in nasal 
polyps and normal mucosa, and the capillaries directly beneath the 
epithelium are mostly fenestrated (Cauna et al. 1972, Watanabe et al. 
1980). Members of the vascular endothelial growth factor family 
(VEGF, placenta growth factor, VEGF-B, VEGF-C and VEGF-D) are 
currently known to be the major inducers of angiogenesis and 
lymphangiogenesis (Saaristo et al. 2000). It is known that VPF/VEGF 
is more powerful than histamine in increasing vascular permeability 
(Senger et al. 1983). The endothelia of small venules and capillaries 
become fenestrated within 10 minutes after VPF/VEGF application 
and VPF/VEGF increases capillary permeability in muscle and skin in 
rats and mice (Roberts and Palade 1995). 
 
We used immunohistochemical staining in the determination of 
VPF/VEGF expression in our study. This method is sensitive but 
semiquantitative. Rather complicated calculations to estimate the 
degrees of positive staining were used. Northern analysis and mRNA 
isolation as used in later studies (Saaristo et al. 2000) would have 
given more exact results.  
 
All chronic polyposis patients in our study had used corticosteroids to 
treat their disease, and it is known that corticosteroids reduce 
VPF/VEGF production (Ristimäki et al. 1998). VPF/VEGF could have 
played a more important role in active, untreated nasal polyposis. 
 
Staining for VPF/VEGF were mostly found in the epithelium of the 
nasal glands. However, in two patients they were found in the mast 
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cells. Although polyps could be seen in anterior rhinoscopy on 33 
patients, loose polypoid stroma was seen only in 25/39 biopsies and 
the remaining biopsies were probably not representative of the polyps. 
Capillaries and small blood vessels were not stained in the samples, 
but those in the pedicles of polyps, may probably have been more 
numerous and thus better suited for analysis. 
 
VPF/VEGF expression was found in the surface epithelium goblet 
cells and in the epithelium of the nasal glands. This indicates the 
possibility that VPF/VEGF could take part in the mucus secretion 
from nasal glands and goblet cells. In a study done later than ours the 
expression of VEGF-C and its receptor VEGFR-3 was found in the 
developing and adult respiratory epithelium and in the nasal vascular 
plexus (Saaristo et al. 2000). In this study immunoperoxidase staining 
for VEGF-C occurred in the cytoplasm of the nasal respiratory 
epithelial cells as well as in the mucus-secreting glands and also 
weakly in the endothelial cells of the VEGFR-2- and VEGFR-3 
positive vessels. It was suggested that secreted growth factor becomes 
concentrated on endothelial cell surfaces displaying its receptor and 
VEGF-C and VEGFR-3 could regulate the permeability of the vessels 
needed for the secretion of nasal mucus and regulation of the lumen of 
the nasal passages.  
 
In another recent study (Coste et al. 2000) VEGF expression was 
evaluated in nasal polyps and control nasal mucosa and VEGF 
positivity was more frequent in inflammatory cells in nasal polyps 
(14/14) than in control nasal mucosa (3/6) (P < 0.05) and in the 
epithelium in nasal polyps (6/14) than in control nasal mucosa (2/6) 
(nonsignificant). 
 
It has earlier been shown that mast cells occur about twice as 
frequently in nasal polyps as in the normal nasal respiratory mucosa 
(Cauna et al. 1972). The mast cell granules of polyps are relatively 
small and they either lack the outer lamellar element or are largely 
degranulated (Cauna et al. 1972). The biopsies in our study were 
mainly taken from the body or apex of the polyps. However, there are 
more mast cells in the pedicle of a polyp and mast cells are more 
degranulated in the pedicle region than in the other parts of a polyp 
(Sasaki 1986). In our study it would have been better to have taken the 
samples from the pedicle part of the polyp. 
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In our study mast cells were largely degranulated, except those mast 
cells which expressed VPF/VEGF in two patients. VPF/VEGF 
expression in mast cells has also been found in other studies. Recently, 
Boesiger et al. (1998) reported that bone marrow-derived cultured 
mouse mast cells and umbilical cord blood derived human mast cells 
produce and secrete VPF/VEGF. The release of VPF/VEGF could be 
regulated differentially from that of preformed mediators such as 5-
hydroxytryptamine (5-HT) and histamine. Grützkau et al. (1998) 
reported that the HMC-1 human mast cell leukaemia cell line can 
constitutively express and secrete three isoforms of VPF/VEGF (of 
121,165 and 189 amino acids). VPF/VEGF-positive mast cells have 
also been found more in the synovium of rheumatoid arthritis patients 
than in the synovium of non-rheumatoid arthritis patients by 
immunostaining (Yamada et al. 1998). The presence of VPF/VEGF in 
non-degranulated mast cells in two polyposis patients implies that the 
release of VPF/VEGF from mast cells in nasal mucosa could 
participate in the pathogenesis of polyps. 
 
 
6.5. THE FREQUENCY OF CF MUTATIONS IN PATIENTS 
WITH CHRONIC SINUSITIS (V) 
 
CF is associated with severe chronic infections in many organs. 
Especially respiratory tract infections, such as sinusitis, are common 
among CF patients and the prevalence of polyps have been reported to 
be 20-48% (di Sant’ Agnese and Davis 1979, Aitken and Fiel 1993) in 
adult patients with CF. This has evoked interest to study whether CF 
heterozygotes are overexpressed in some chronic infections and nasal 
polyposis. Such an association has been found in chronic bronchial 
hypersecretion (Dumur et al. 1990), non-alcoholic pancreatitis (Sharer 
et al. 1998), and chronic sinusitis (Wang et al. 1998). There are also 
reports of diseases in which the CF carrier incidence has not increased: 
Akai et al. (1992) studied diffuse panbronchiolitis and Irving et al. 
(1997) severe nasal polyposis patients. 
 
Interest in genetic diagnostics has increased in the past years, as the 
new technology has produced methods to displace genetic defects and 
thus to treat some hereditary diseases (Crystal et al. 1994, Wagner et 
al. 1998). 
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This study screening for two of the most common mutations in 127 
chronic sinusitis patients identified only one carrier of a 394delTT 
mutation without nasal polyposis. The study population is somewhat 
small and thus we can not completely rule out some association 
between chronic sinusitis and CF. However, it is possible to find limits 
for the plausible values of prevalence. In a study with 127 participants, 
it can be calculated using binomial distribution that in order for the 
probability of finding none or at most one mutation to be at least 5% 
the prevalence of the mutation must be less than 0.024 or 0.036, 
respectively i.e. 5% level higher than 2.4% and 3.5%. The F508 and 
394delTT mutations studied account for 75% of the CF mutations in 
Finland. It is quite improbable that those rare mutations that were not 
included in the study would be overexpressed in the chronic sinusitis 
population.  
 
This study showed that in a population with a low-incidence of CF 
there was not an abnormal carrier distribution of CF gene mutations in 
a group of chronic sinusitis patients with or without nasal polyps. 
Routine screening of sinusitis patients with or without nasal polyps for 
CF mutations does not seem to have given any more information about 
the etiology of chronic sinusitis. 
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CONCLUSIONS 
 
 
1. Sixty-eight percent of 41 patients thought that over 20 years the 
activity of their disease had decreased or the disease had been 
resolved. However polyps could be seen in anterior rhinoscopy in 
85% of the patients, hyposmia or anosmia was found in 46% of the 
patients and in sinus CT all the paranasal sinuses were found to be 
heavily or moderately obliterated in 34% of the patients and some 
of the sinuses in 39% and normal mucosa through all the paranasal 
sinuses was not found suggesting an active disease and indications 
for some treatment and continuous follow-up. The patients with 
ASA intolerance had a higher recurrence frequency, and a greater 
need for surgical treatment than the patients in the AT and INTR 
groups.  
2. A-US should not be used in patients with a history of chronic 
sinusitis, polyposis and especially in transantrally operated 
maxillary sinuses although it can be a valuable investigation 
method in cases of simple acute sinusitis. There are many sources 
of errors when A-US is used for diagnosing acute exacerbations of 
chronic polypoid or operated sinuses. Firstly, antral mucosal 
swelling with polypoid masses may be so thick as to give 
ultrasonographic echoes which are suggestive of fluid retention or 
total obliteration. Secondly, transantral operations on the maxillary 
sinus cause deformation of the anatomy, which makes diagnostic 
conclusions difficult.  
3. Chronic nasal polyposis diminishes the sense of smell, probably 
mainly due to conductive mechanisms. But worsening of the sense 
of smell without simultaneous obstruction in the olfactory region as 
seen by CT in some cases may also be due to perceptive lesions. 
4. The staining for VPF/VEGF in the mucosal surface and in the 
glandular epithelium of nasal polyps was weaker than in normal 
controls. In two patients strong staining for VPF/VEGF was found 
in the granules of mast cells, while the mast cells in other polyposis 
patients appeared to be largely degranulated. VPF/VEGF was not 
seen in the mast cells of control patients. This finding needs further 
study to find out if VPF/VEGF are secreted from mast cells and 
have a role in nasal polyp formation. 
5. In the Finnish population with its low-incidence of CF there was 
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not an abnormal carrier distribution of CF gene mutations in the 
studied group of chronic sinusitis patients with or without nasal 
polyposis. Routine screening of sinusitis patients for CF mutations 
gives no more information on the etiology of chronic sinusitis. 
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